Document:

Purchase Agreement, dated as of June 13, 2003

 Exhibit 10.66 
  
 CV THERAPEUTICS, INC. 
  
 $100,000,000 2.0% Senior Subordinated Convertible 
 Debentures Due 2023 
  
 PURCHASE AGREEMENT 
  
 New York, New York

 June 13, 2003 
  
 CITIGROUP GLOBAL MARKETS INC. 
 CIBC WORLD MARKETS CORP. 
 DEUTSCHE BANK SECURITIES INC. 
 FIRST ALBANY CORPORATION 
 NEEDHAM & COMPANY, INC. 
 SG COWEN SECURITIES CORPORATION 
 As Representatives of the several Initial Purchasers 
 named in Schedule I hereto 
 c/o Citigroup Global Markets Inc. 
 388 Greenwich Street 
 New York, New York 10013 
  
 Ladies and Gentlemen: 
  
 CV
Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several parties named in Schedule I hereto (the “Initial Purchasers”),
for whom you (the “Representatives”) are acting as representatives, $100,000,000 aggregate principal amount of its 2.0% senior subordinated convertible debentures due 2023 (the “Firm Securities”) and, at the
election of the Initial Purchasers, of up to $25,000,000 additional aggregate principal amount thereof (the “Option Securities”) (the Firm Securities and Option Securities which the Initial Purchasers elect to purchase pursuant to
this Agreement being collectively referred to as the “Securities”) convertible into shares of common stock, par value $.001 per share (the “Shares”) of the Company. The Securities will be issued pursuant to an
indenture (the “Indenture”), to be dated as of the Closing Date (as defined below), between the Company and Wells Fargo Bank, N.A., as trustee (the “Trustee”). The Securities will have the benefit of a registration
rights agreement (the “Registration Rights Agreement”), to be dated as of the Closing Date, between the Company and the Initial Purchasers, pursuant to which the Company will agree to register the Securities under the Act subject to
the terms and conditions therein specified. The Company will enter into a pledge and escrow agreement (the “Escrow Agreement”), to be dated as of the Closing Date, pursuant to which the Company will deposit on the Closing Date funds
sufficient to make the first six scheduled interest payments on the Securities. To the extent there are no additional parties listed on Schedule I other than you, the term “Representatives” as used 

 
herein shall mean you as the Initial Purchasers, and the terms Representatives and Initial Purchasers shall mean either the singular or plural as the context
requires. The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Certain terms used herein are defined in Section 18 hereof. 
  
 The sale of the Securities to the Initial Purchasers will be made without registration of the Securities under the Act in
reliance upon exemptions from the registration requirements thereof. 
  
 In connection with the sale of the Securities, the Company has prepared a preliminary offering memorandum, dated June 12, 2003 (as amended or supplemented at the Execution Time, including any and all exhibits thereto and any information
incorporated by reference therein, the “Preliminary Memorandum”), and a final offering memorandum, dated June 13, 2003 (as amended or supplemented at the Execution Time, including any and all exhibits thereto and any information
incorporated by reference therein, the “Final Memorandum”). Each of the Preliminary Memorandum and the Final Memorandum sets forth certain information concerning the Company and the Securities. The Company hereby confirms that it
has authorized the use of the Preliminary Memorandum and the Final Memorandum, and any amendment or supplement thereto, in connection with the offer and sale of the Securities by the Initial Purchasers. Unless stated to the contrary, any references
herein to the terms “amend,” “amendment” or “supplement” with respect to the Final Memorandum shall be deemed to refer to and include any information filed under the Exchange Act subsequent to the Execution Time which
is incorporated by reference therein. 
  
 1. Representations
and Warranties. The Company represents and warrants to each Initial Purchaser as set forth below in this Section 1. 
  
 (a) The Preliminary Memorandum, at the date thereof, did not contain any untrue statement of a material fact or omit to state any material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. At the Execution Time, on the Closing Date and on any Additional Closing Date, the Final Memorandum did not, and will not
(and any amendment or supplement thereto, at the date thereof, at the Closing Date and on any Additional Closing Date, will not), contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representation or warranty as to the information contained in or omitted from the Preliminary
Memorandum or the Final Memorandum, or any amendment or supplement thereto, in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of the Initial Purchasers through the Representatives specifically
for inclusion therein. 
  
 (b) Neither the
Company, nor any of its Affiliates, nor any person acting on its or their behalf has, directly or indirectly, made offers or sales of any security, or 

  

 2 

 
solicited offers to buy any security, under circumstances that would require the registration of the Securities under the Act. 
  
 (c) Neither the Company, nor any of its Affiliates, nor any
person acting on its or their behalf (other than the Initial Purchasers, as to which the Company makes no representation) has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with
any offer or sale of the Securities in the United States. 
  
 (d) The Securities satisfy the eligibility requirements of Rule 144A(d)(3) under the Act. 
  
 (e) Neither the Company, nor any of its Affiliates, nor any person acting on its or their behalf has engaged in any directed selling
efforts with respect to the Securities, and each of them has complied with the offering restrictions requirements of Regulation S. Terms used in this paragraph have the meanings given to them by Regulation S. 
  
 (f) The Company expects that the Securities will be
designated PORTAL-eligible securities by the NASD’s PORTAL MARKET prior to the Closing Date in accordance with the rules and regulations of the NASD. 
  
 (g) The Company is subject to and in full compliance with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act.

  
 (h) The Company has not paid or agreed to pay
to any person any compensation for soliciting another to purchase any securities of the Company (except as contemplated by this Agreement). 
  
 (i) The Company has not taken, directly or indirectly, any action designed to cause or which has constituted or which might reasonably be
expected to cause or result, under the Exchange Act or otherwise, in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities. 
  
 (j) The Company has been duly incorporated and is validly
existing as a corporation in good standing under the laws of its jurisdiction of incorporation, is duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which its ownership or lease of property or the
conduct of its business requires such qualification, and has all power and authority necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to so qualify or have such power or authority
would not have, singularly or in the aggregate, a material adverse effect on the condition (financial or otherwise), results of operations, business or prospects of the Company (a “Material Adverse Effect”). Except for CV
Therapeutics Europe Limited, the Company’s wholly-owned subsidiary, 

  

 3 

 
the Company does not own or control, directly or indirectly, any corporations, associations or other entities. 
  
 (k) The Company’s authorized equity capitalization is
as set forth in the Final Memorandum and the Common Stock conforms in all material respects to the description thereof contained in the Final Memorandum; all of the issued shares of capital stock of the Company have been duly and validly authorized
and issued, are fully paid and nonassessable and conform to the description thereof contained in the Final Memorandum; the Shares initially issuable upon conversion of the Securities have been duly and validly authorized and, when issued upon
conversion in accordance with the terms of the Securities and the Indenture, will be validly issued, fully paid and nonassessable; the Board of Directors of the Company or a duly constituted committee thereof has duly and validly adopted resolutions
reserving such Shares for issuance upon conversion; and, except as set forth in the Final Memorandum, no options, warrants, or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations into or exchange
any securities for shares of capital stock or ownership interest in the Company are outstanding. 
  
 (l) This Agreement has been duly authorized, executed and delivered by the Company; the Indenture has been duly authorized and, assuming
due authorization, execution and delivery thereof by the Trustee, when executed and delivered by the Company, will constitute a legal, valid and binding instrument enforceable against the Company in accordance with its terms (subject, as to the
enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors’ rights generally from time to time in effect and to general principles of equity); the Securities have been duly
authorized, and, when executed and authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchasers, will have been duly executed and delivered by the Company and will constitute legal, valid
and binding obligations of the Company, entitled to the benefits of the Indenture and enforceable against the Company in accordance with their terms (subject, as to the enforcement of remedies, to applicable bankruptcy, insolvency, moratorium or
other laws affecting creditors’ rights generally from time to time in effect and to general principles of equity); the Registration Rights Agreement has been duly authorized and, when executed and delivered by the Company, will constitute a
legal, valid and binding instrument enforceable against the Company in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors’
rights generally from time to time in effect and to general principles of equity); and the Escrow Agreement has been duly authorized and, when executed and delivered by the Company, will constitute a legal, valid and binding instrument enforceable
against the Company in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors’ rights generally from time to time in effect and
to general principles of equity). 
  

 4 

 (m) The execution, delivery and performance of this Agreement by the Company and the
consummation of the transactions contemplated hereby will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject, nor will such actions result in any violation of the provisions of the charter or by-laws
of the Company or any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its properties or assets. 
  
 (n) Ernst & Young LLP, who have expressed their opinions on the audited financial statements and related
schedules incorporated by reference in the Final Memorandum, are independent public accountants as required by the Securities Act. 
  
 (o) The financial statements, together with the related notes and schedules incorporated by reference in the Final Memorandum, fairly
present the financial position and the results of operations and changes in financial position of the Company at the respective dates or for the respective periods therein specified. Such statements and related notes and schedules have been prepared
in accordance with generally accepted accounting principles applied on a consistent basis except as may be set forth in the Final Memorandum. 
  
 (p) The Company has not sustained, since the date of the latest audited financial statements included or incorporated by reference in the
Final Memorandum, any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as
set forth or contemplated in the Final Memorandum; and, since such date, there has not been any material change in the capital stock or long-term debt of the Company or any material adverse change, or any development involving a prospective material
adverse change, in or affecting the business, general affairs, management, financial position, stockholders’ equity or results of operations of the Company (a “Material Adverse Change”), otherwise than as set forth or
contemplated in the Final Memorandum. 
  
 (q)
Except as set forth in the Final Memorandum, there is no legal or governmental proceeding pending to which the Company is a party or of which any property or assets of the Company is the subject which, singularly or in the aggregate, if determined
adversely to the Company, might have a Material Adverse Effect or would prevent or adversely affect the ability of the Company to perform its obligations under this Agreement; and to the best of the Company’s knowledge, no such proceedings are
threatened or contemplated by governmental authorities or threatened by others. 
  
 (r) The Company (i) is not in violation of its charter or by-laws, (ii) is not in default in any respect, and no event has occurred which,
with notice or lapse of time 

  

 5 

 
or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject and (iii) is not in violation in any respect of any law, ordinance, governmental rule,
regulation or court decree to which it or its property or assets may be subject except, with respect to clauses (ii) and (iii), any violations or defaults which, singularly or in the aggregate, would not have a Material Adverse Effect. 

 
 (s) The Company possesses such permits, licenses,
approvals, consents and other authorizations (including licenses, pharmacy licenses, accreditation and other similar documentation or approvals of any local health departments) (collectively, “Governmental Licenses”) issued by the
appropriate federal, state, local or foreign regulatory agencies or bodies, including, without limitation, the United States Food and Drug Administration (“FDA”), necessary to conduct the business now operated by it; the Company is
in compliance with the terms and conditions of all such Governmental Licenses and all applicable FDA rules and regulations, guidelines and policies, except where the failure so to comply could not reasonably be expected to, singularly or in the
aggregate, result in a Material Adverse Effect; all of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and
effect could not reasonably be expected to result in a Material Adverse Effect; and the Company has not received any notice of proceedings relating to the revocation or modification of any such Governmental Licenses which, singularly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding, could reasonably be expected to result in a Material Adverse Effect. 
  
 (t) The Company owns or possesses adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property, including, without limitation, all of the intellectual property described in
the Final Memorandum as being owned or licensed by the Company (collectively, “Intellectual Property”), necessary to carry on the business now operated by it. Except as set forth in the Final Memorandum (exclusive of any amendments
thereto after the date hereof), no valid U.S. patent is, or to the knowledge of the Company would be, infringed by the activities of the Company in the manufacture, use, offer for sale or sale of any product or component thereof as described in the
Final Memorandum. The patent applications (the “Patent Applications”) filed by or on behalf of the Company described in the Final Memorandum have been properly prepared and filed on behalf of the Company; except as set forth in the
Final Memorandum (exclusive of any amendments thereto after the date hereof) each of the Patent Applications and patents (the “Patents”) described in the Final Memorandum is assigned or licensed to the Company, and, except as set
forth in the Final Memorandum (exclusive of any amendments thereto after the 

  

 6 

 
date hereof), no other entity or individual has any right or claim in any Patent, Patent Application or any patent to be issued therefrom; and, to the
knowledge of the Company, each of the Patent Applications discloses potentially patentable subject matter. There are no actions, suits or judicial proceedings pending relating to patents or proprietary information to which the Company is a party or
of which any property of the Company is subject and the Company has not received any notice and is not otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or
circumstances which could render any Intellectual Property invalid or inadequate to protect the interest of the Company therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or
inadequacy, singly or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. 
  
 (u) The human clinical trials conducted by the Company or in which the Company has participated relating to ranolazine, tecadenoson and
CVT-3146 that are described in the Final Memorandum, or the results of which are referred to in the Final Memorandum, if any, are the only human clinical trials currently being conducted by or on behalf of the Company, and, to the best of the
Company’s knowledge, such studies and tests were and, if still pending, are being, conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards; the descriptions of the
results of such studies, tests and trials contained in the Final Memorandum, if any, are accurate and complete in all material respects. The Company has no knowledge of any other studies or tests, the results of which call into question the results
of the clinical trials described in the Final Memorandum. The Company has not received any notices or correspondence from the FDA or any other governmental agency requiring the termination, suspension or modification of any clinical trials conducted
by, or on behalf of, the Company or in which the Company has participated that are described in the Final Memorandum, if any, or the results of which are referred to in the Final Memorandum. All human clinical trials previously conducted by or on
behalf of the Company while conducted by or on behalf of the Company, were conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards; the descriptions of the results of such
studies, tests and trials contained in the Final Memorandum, if any, are accurate and complete in all material respects. 
  
 (v) The Company is not and, after giving effect to the offering of the Securities and the application of the proceeds thereof as described
in the Final Memorandum, will not become an “investment company” within the meaning of the Investment Company Act of 1940, as amended (the “Investment Company Act”) and the rules and regulations of the Commission
thereunder. 
  
 (w) Neither the Company nor any
of its officers, directors or affiliates has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, 

  

 7 

 
or which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company.

  
 (x) The Company has good and marketable title
in fee simple to, or has valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company, in each case free and clear of all liens, encumbrances, claims and defects that may result in
a Material Adverse Effect. 
  
 (y) No labor
disturbance by the employees of the Company exists or, to the best of the Company’s knowledge, is imminent which might be expected to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of
employees of the Company plans to terminate employment with the Company. 
  
 (z) No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder
(“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any of the events set
forth in Section 4043(b) of ERISA (other than events with respect to which the 30-day notice requirement under Section 4043 of ERISA has been waived) has occurred with respect to any employee benefit plan which could have a Material Adverse Effect;
each employee benefit plan is in compliance in all material respects with applicable law, including ERISA and the Code; the Company has not incurred and does not expect to incur liability under Title IV of ERISA with respect to the termination of,
or withdrawal from, any “pension plan”; and each “pension plan” (as defined in ERISA) for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all
material respects and nothing has occurred, whether by action or by failure to act, which could cause the loss of such qualifications. 
  
 (aa) There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any
kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company (or, to the best of the Company’s knowledge, any other entity for whose acts or omissions the Company is or may be liable) upon any of the property
now or previously owned or leased by the Company, or upon any other property, in violation of any statute or any ordinance, rule, regulation, order, judgment, decree or permit or which would, under any statute or any ordinance, rule (including rule
of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which would not have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse
Effect; there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect 

  

 8 

 
to which the Company has knowledge, except for any such disposal, discharge, emission, or other release of any kind which would not have, singularly or in
the aggregate with all such discharges and other releases, a Material Adverse Effect. 
  
 (bb) The Company (i) has filed all necessary federal, state and foreign income and franchise tax returns or has duly requested extensions
thereof, (ii) has paid all federal, state, local and foreign taxes due and payable for which it is liable, except to the extent that any such taxes are being contested in good faith and by appropriate proceedings, and (iii) does not have any tax
deficiency or claims outstanding or assessed or, to the best of the Company’s knowledge, proposed against it which, in each of the cases described in clauses (i), (ii) and (iii), could reasonably be expected to have a Material Adverse Effect.

  
 (cc) The Common Stock is registered pursuant
to Section 12(g) of the Exchange Act and is listed on the Nasdaq National Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting
the Common Stock from the Nasdaq National Market, nor has the Company received any notification that the Commission or the NASD is contemplating terminating such registration or listing. 
  
 (dd) The Company carries, or is covered by, insurance in such amounts and covering such risks as is adequate
for the conduct of its businesses and the value of its properties and as is customary for companies engaged in similar businesses in similar industries. 
  
 (ee) The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are
executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain
accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. 
  
 (ff) The minute books of the Company have been made available to the Initial Purchasers and counsel for the Initial Purchasers, and such books (i) contain a complete summary of all meetings and actions of the
directors and stockholders of the Company since the time of its respective incorporation through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred to in such minutes.

  
 (gg) No relationship, direct or indirect,
exists between or among the Company on the one hand, and the directors, officers, stockholders, customers or suppliers 

  

 9 

 
of the Company on the other hand, which is required to be described in the Final Memorandum and which is not so described. 
  
 (hh) No person or entity has the right to require
registration of shares of Common Stock or other securities of the Company (other than the Securities) as a result of or in connection with the transactions contemplated by this Agreement or the Registration Rights Agreement, except for persons and
entities who have expressly waived such right or who have been given proper notice and have failed to exercise such right within the time or times required under the terms and conditions of such right. 
  
 (ii) The Company does not own any “margin
securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of the sale of the Securities will be used, directly or
indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any
of the Securities to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board. 
  
 (jj) The Company is not a party to any contract, agreement or understanding with any person that would give rise to a valid claim against
the Company or the Initial Purchasers for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Securities. 
  

(kk) No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act)
contained or incorporated by reference in the Final Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 
  
 (ll) The Company has not distributed and, prior to the later of (i) the Closing Date and (ii) the completion
of the distribution of the Securities, will not distribute any written offering material in connection with the offering and sale of the Securities other than the Preliminary Memorandum and the Final Memorandum or any amendment thereto. 

 
 2. Purchase and Sale. (a) Subject to the terms and conditions and
in reliance upon the representations and warranties herein set forth, on the Closing Date, the Company agrees to sell to each Initial Purchaser, and each Initial Purchaser agrees, severally and not jointly, to purchase from the Company, at a
purchase price of 97% of the principal amount thereof, plus accrued interest, if any, from June 18, 2003 to the Closing Date, the aggregate principal amount of Securities set forth opposite such Initial Purchaser’s name in Schedule I
hereto. 
  

 10 

 (b) Subject to the terms and conditions and in reliance upon the representations and warranties herein
set forth, the Company hereby grants an option to the several Initial Purchasers to purchase, severally and not jointly, the Option Securities at the same purchase price as the Initial Purchasers paid for the Firm Securities, plus accrued interest,
if any, from June 18, 2003 to the Additional Closing Date. The option may be exercised in whole or in part at any time (but not more than once) on or before the 30th day after the date of the Final Memorandum upon written or telegraphic notice by
the Representatives to the Company setting forth the number of Option Securities as to which the Initial Purchasers are exercising the option and the settlement date. Delivery of the Option Securities, and payment therefor, shall be made as provided
in Section 3 hereof. The principal amount of Option Securities to be purchased by each Initial Purchaser shall be the same percentage of the total number of Option Securities to be purchased by the Initial Purchasers as such Initial Purchaser is
purchasing of the Firm Securities, subject to such adjustments as the Representatives shall deem advisable. 
  
 3. Delivery and Payment. Delivery of and payment for the Securities shall be made at 10:00 A.M., New York City time, on June 18, 2003, or at such
time on such later date (not later than June 25, 2003) as the Representatives shall designate, which date and time may be postponed by agreement between the Representatives and the Company or as provided in Section 9 hereof (such date and time of
delivery and payment for the Securities being herein called the “Closing Date”). Delivery of the Securities shall be made to the Representatives for the respective accounts of the several Initial Purchasers against payment by the
several Initial Purchasers through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in same-day funds to the account specified by the Company. Delivery of the Securities shall be made
through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. 
  
 If the option provided for in Section 2(b) hereof is exercised after the third Business Day prior to the Closing Date, the Company will deliver the Option
Securities (at the expense of the Company) to the Representatives on the date specified by the Representatives (which shall be within three Business Days after exercise of said option), for the respective accounts of the several Initial Purchasers,
against payment by the several Initial Purchasers through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in same-day funds to the account specified by the Company. If settlement for the
Option Securities occurs after the Closing Date, the Company will deliver to the Representatives on the settlement date for the Option Securities (the “Additional Closing Date”), and the obligation of the Initial Purchasers to
purchase the Option Securities shall be conditioned upon receipt of supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and letters delivered on the Closing Date pursuant to Section 6 hereof.

  
 4. Offering by Initial Purchasers. Each Initial
Purchaser, severally and not jointly, represents and warrants to and agrees with the the Company as follows: 
  

 11 

 (a) It has not offered or sold, and will not offer or sell, any Securities except (i) to
those it reasonably believes to be qualified institutional buyers (as defined in Rule 144A under the Act) and that, in connection with each such sale, it has taken or will take reasonable steps to ensure that the purchaser of such Securities is
aware that such sale is being made in reliance on Rule 144A; or (ii) in accordance with the restrictions set forth in Exhibit A hereto. 
  
 (b) Neither it nor any person acting on its behalf (i) has made or will make offers or sales of the Securities in the United States by
means of any form of general solicitation or general advertising (within the meaning of Regulation D) in the United States or (ii) has engaged or will engage in any directed selling efforts with respect to the Securities, and each such person has
complied and will comply with the offering restrictions of Rule 144A. 
  
 (c) It is a “qualified institutional buyer” within the meaning of Rule 144A under the Act. 
  
 (d) Such Initial Purchaser will take reasonable steps to inform, and cause each of its Affiliates to take reasonable steps to inform
persons acquiring Securities from such Initial Purchaser or Affiliate, as the case may be, in the United States that (i) the offering and sale of the Securities have not been and will not be registered under the Act, (ii) the Securities are being
sold to them without registration under the Act in reliance on Rule 144A or in accordance with the requirements set forth in Exhibit A hereto and (iii) the Securities may not be offered, sold or otherwise transferred except (A) to the
Company, (B) pursuant to a registration statement that has been declared effective under the Act, or (C) in accordance with (1) Rule 144A to a person whom the seller reasonably believes is a qualified institutional buyer that is purchasing such
Securities for its own account or for the account of a qualified institutional buyer to whom notice is given that the offer, sale or transfer is being made in reliance on Rule 144A or (2) pursuant to another available exemption from registration
under the Act. 
  
 (e) The transfer restrictions
and the other provisions set forth in the Final Memorandum under the heading “Transfer Restrictions,” including the legend required thereby, shall apply to the Securities except as otherwise agreed by the Company and the Initial
Purchasers. 
  
 5. Agreements. The Company agrees with each
Initial Purchaser as follows: 
  
 (a) The Company
will furnish to each Initial Purchaser and to counsel for the Initial Purchasers, without charge, during the period referred to in paragraph (c) below, as many copies of the Final Memorandum and any amendments and supplements thereto as they may
reasonably request. 
  

 12 

 (b) The Company will not amend or supplement the Final Memorandum without the prior
written consent of the Representatives, which consent shall not be unreasonably withheld; provided, however, that prior to the Closing Date, the Company will not amend the Final Memorandum to incorporate by reference any document under
the Exchange Act unless, prior to such proposed filing, the Company has furnished the Representatives with a copy of such document for their review and the Representatives have not reasonably objected to the filing of such document. Prior to the
Closing Date, the Company will promptly advise the Representatives when any document filed under the Exchange Act that is incorporated by reference in the Final Memorandum shall have been filed with the Commission. 
  
 (c) If at any time prior to the notification by the Initial
Purchasers to the Company of the completion of the sale of the Securities by the Initial Purchasers, any event occurs as a result of which the Final Memorandum, as then amended or supplemented, would include any untrue statement of a material fact
or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if it should be necessary to amend or supplement the Final Memorandum to comply with
applicable law, the Company promptly (i) will notify the Representatives of any such event; (ii) subject to the requirements of paragraph (b) of this Section 5, will prepare an amendment or supplement that will correct such statement or omission or
effect such compliance; and (iii) will supply any supplemented or amended Final Memorandum to the several Initial Purchasers and counsel for the Initial Purchasers without charge in such quantities as they may reasonably request. 
  
 (d) The Company will arrange, if necessary, for the
qualification of the Securities for sale by the Initial Purchasers under the laws of such jurisdictions as the Initial Purchasers may designate and will maintain such qualifications in effect so long as required for the sale of the Securities;
provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits generally, other than those
arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so subject. The Company will promptly advise the Representatives of the receipt by the Company of any notification with respect to the suspension of the
qualification of the Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose. 
  
 (e) Other than pursuant to the Registration Rights Agreement, neither the Company, nor any of its Affiliates, nor any person acting on its
or their behalf (other than the Initial Purchasers, as to which the Company makes no covenant) will, directly or indirectly, make offers or sales of any security, or solicit offers to buy any security, under circumstances that would require the
registration of the Securities under the Act. 
  

 13 

 (f) Other than pursuant to the Registration Rights Agreement, neither the Company nor any
of its Affiliates, nor any person acting on its or their behalf (other than the Initial Purchasers, as to which the Company makes no covenant) will engage in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with any offer or sale of the Securities in the United States. 
  
 (g) So long as any of the Securities are “restricted securities” within the meaning of Rule 144(a)(3) under the Act, the
Company will, during any period in which it is not subject to and in compliance with Section 13 or 15(d) of the Exchange Act or it is not exempt from such reporting requirements pursuant to and in compliance with Rule 12g3-2(b) under the Exchange
Act, provide to each holder of such restricted securities and to each prospective purchaser (as designated by such holder) of such restricted securities, upon the written request of such holder or prospective purchaser, any information required to
be provided by Rule 144A(d)(4) under the Act. This covenant is intended to be for the benefit of the holders, and the prospective purchasers designated by such holders, from time to time of such restricted securities. 
  
 (h) Neither the Company nor any of its Affiliates, nor any
person acting on its or their behalf (other than the Initial Purchasers, as to which the Company makes no covenant) will engage in any directed selling efforts with respect to the Securities, and each of them will comply with the offering
restrictions requirement of Regulation S. Terms used in this paragraph have the meanings given to them by Regulation S. 
  
 (i) The Company will cooperate with the Representatives and use its reasonable best efforts to permit the Securities to be eligible for
clearance and settlement through The Depository Trust Company. 
  
 (j) For a period of 90 days from the date of the Final Memorandum, the Company will not, directly or indirectly, (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or
exchangeable for Common Stock or (ii) enter into any swap, option, future, forward or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise without the prior written consent of Citigroup, which shall not be unreasonably withheld, other than (i) any shares of Common Stock
of the Company issued upon the conversion of any convertible notes or debentures (including, without limitation, the Securities) or convertible preferred stock or the exercise of options, warrants and rights outstanding on the date of the Final
Memorandum, (ii) options or rights granted or stock issued and sold under existing employee stock purchase or option plans or the issuance of any rights thereunder by the Company or (iii) shares of Common Stock issued and sold pursuant to 

  

 14 

 
the Company’s existing effective shelf registration statements resulting in aggregate net proceeds not to exceed $50.0 million. Notwithstanding the
restrictions in the preceding sentence, the Company shall be permitted to execute definitive documentation with Acqua Wellington North American Equities Fund, Ltd. with respect to its potential equity line of credit arrangement, including, but not
limited to, a stock purchase agreement, during the 90-day period following the date of the Final Offering Memorandum without violating the provisions of this Section 5(j). 
  
 (k) The Company will not take, directly or indirectly, any action designed to or which has constituted or
which might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities. 
  
 (l) The Company shall not, and shall cause its Affiliates
not to, seek the release of the funds held in the Escrow Account (as defined in the Escrow Agreement) unless such release is in compliance with the terms of the Indenture and the Escrow Agreement. 
  
 (m) The Company agrees to pay the costs and expenses
relating to the following matters: (i) the preparation of the Indenture, the Registration Rights Agreement, the Escrow Agreement, the issuance of the Securities and the fees of the Trustee under the Escrow Agreement; (ii) the preparation, printing
or reproduction of the Preliminary Memorandum and Final Memorandum and each amendment or supplement to either of them; (iii) the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging)
of such copies of the Preliminary Memorandum and Final Memorandum, and all amendments or supplements to either of them, as may, in each case, be reasonably requested for use in connection with the offering and sale of the Securities; (iv) the
preparation, printing, authentication, issuance and delivery of certificates for the Securities, including any stamp or transfer taxes in connection with the original issuance and sale of the Securities; (v) the printing (or reproduction) and
delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the Securities; (vi) any registration or qualification of the Securities for offer and
sale under the securities or blue sky laws of the several states (including filing fees and the reasonable fees and expenses of counsel for the Initial Purchasers relating to such registration and qualification not to exceed $5,000); (vii) applying
for the Securities to be traded in the PORTAL Market; (viii) the transportation and other expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Securities; (ix) the fees and
expenses of the Company’s accountants and the fees and expenses of counsel (including local and special counsel) for the Company; and (x) all other costs and expenses incident to the performance by the Company of its obligations hereunder. It
is expressly understood that except as provided in the Agreement, the Initial Purchasers 
  

 15 

 
will pay for their own expenses, including the fees of their counsel and any transfer taxes in connection with the resale of the Securities by them.

  
 (n) The Company shall apply the net proceeds
of the offering of the Securities as described in the “Use of Proceeds” section of the Final Memorandum. 
  
 6. Conditions to the Obligations of the Initial Purchasers. The obligations of the Initial Purchasers to purchase the Securities shall be subject
to the accuracy of the representations and warranties on the part of the Company contained herein at the Execution Time, the Closing Date and any Additional Closing Date pursuant to Section 3 hereof, to the accuracy of the statements of the Company
made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and to the following additional conditions: 
  
 (a) Latham & Watkins, special counsel for the Company, shall have furnished to the Initial Purchasers
their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, in form and substance satisfactory to the Representatives, in substantially the form attached hereto as Exhibit B. 
  
 (b) Tricia Borga Suvari, General Counsel for the Company,
shall have furnished to the Initial Purchasers her written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, in form and substance satisfactory to the Representatives, in substantially the form attached hereto as
Exhibit C. 
  
 (c) The Representatives
shall have received from Cahill Gordon & Reindel LLP, counsel for the Initial Purchasers, such opinion or opinions, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Representatives, with respect to
the issuance and sale of the Securities, the Indenture, the Registration Rights Agreement, the Final Memorandum (as amended or supplemented at the Closing Date) and other related matters as the Representatives may reasonably require, and the Company
shall have furnished to such counsel such documents as they reasonably request for the purpose of enabling them to pass upon such matters. 
  
 (d) The Company shall have furnished to the Representatives a certificate of the Company signed by the chief executive officer and any of
the chief financial officer, the treasurer and the principal accounting officer of the Company, dated the Closing Date, to the effect that the signers of such certificate have carefully examined the Final Memorandum, any amendment or supplement to
the Final Memorandum and this Agreement and that: 
  
 (i) the representations and warranties of the Company in this Agreement are true and correct in all material respects on and as of the Closing Date with the same effect as if made on the Closing Date, and the Company has complied in all
material respects with all agreements and satisfied all con- 
  

 16 

 
ditions on their part to be performed or satisfied hereunder at or prior to the Closing Date; and 
  
 (ii) since the date of the most recent financial statements
included in the Final Memorandum, there has been no event or occurrence that would reasonably be expected to result in a Material Adverse Effect, except as set forth in or contemplated by the Final Memorandum. 
  
 (e) At the Execution Time and at the Closing Date, the
Company shall have requested and caused Ernst & Young LLP to furnish to the Representatives comfort letters regarding the Company, dated respectively as of the Execution Time and as of the Closing Date, in form and substance satisfactory to the
Representatives. 
  
 (f) Subsequent to the
Execution Time or, if earlier, the dates as of which information is given in the Final Memorandum, there shall not have been (i) any change or decrease specified in the letter or letters referred to in paragraph (e) of this Section 6; or (ii) any
change, or any development involving a prospective change, in or affecting the financial condition, results of operations, business operations, assets or liabilities of the Company and its subsidiaries, taken as a whole, except as set forth in or
contemplated by the Final Memorandum, the effect of which is, in the reasonable judgment of the Representatives, so material and adverse as to make it impractical or inadvisable to market the Securities as contemplated by the Final Memorandum.

  
 (g) At the Closing Date, the Company and the
Trustee shall have entered into the Indenture and the Representatives shall have received counterparts, conformed as executed, thereof. 
  
 (h) At the Closing Date, the Company and the Initial Purchasers shall have entered into the Registration Rights Agreement and the
Representatives shall have received counterparts, conformed as executed, thereof. 
  
 (i) At the Closing Date, the Company and the Trustee shall have entered into the Escrow Agreement and the Representatives shall have
received counterparts, conformed as executed, thereof. 
  
 (j) At the Closing Date, the Securities shall be eligible for clearance and settlement through the Depository Trust Company. 
  
 (k) At the Closing Date, the Securities shall have been designated as PORTAL-eligible securities in accordance with the rules and
regulations of the NASD. 
  
 (l) Subsequent to
the Execution Time, there shall not have been any decrease in the rating of any of the Company’s debt securities by any “nationally recognized statistical rating organization” (as defined for purposes of Rule 436(g) under the

  

 17 

 Act) or any notice given of any intended or potential decrease in any such rating or of a
possible change in any such rating that does not indicate the direction of the possible change. 
  
 (m) The “lock-up” agreements, each substantially in the form of Exhibit D hereto, between the Representatives on the one
hand, and each of the executive officers and directors of the Company, on the other hand, relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be
in full force and effect on the Closing Date or Additional Closing Date, as the case may be. 
  
 (n) Prior to the Closing Date, the Company shall have furnished to the Representatives such further information, certificates and
documents as the Representatives may reasonably request. 
  
 If
any of the conditions specified in this Section 6 shall not have been fulfilled in all material respects when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be
in all material respects reasonably satisfactory in form and substance to the Representatives and counsel for the Initial Purchasers, this Agreement and all obligations of the Initial Purchasers hereunder may be canceled at, or at any time prior to,
the Closing Date by the Representatives. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing. 
  

The documents required to be delivered by this Section 6 will be delivered at the office of Cahill Gordon & Reindel LLP, New York, New York on the
Closing Date. 
  
 7. Reimbursement of Expenses. If the sale
of the Securities provided for herein is not consummated because any condition to the obligations of the Initial Purchasers set forth in Section 6 hereof is not satisfied because of any refusal, inability or failure on the part of the Company to
perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Initial Purchasers, the Company will reimburse the Initial Purchasers severally through Citigroup on demand for all out-of-pocket
expenses (including reasonable fees and disbursements of counsel) that shall have been incurred by them in connection with the proposed purchase and sale of the Securities. 
  
 8. Indemnification and Contribution. (a) The Company agrees to indemnify and hold harmless each Initial Purchaser,
the directors, officers, employees and agents of each Initial Purchaser and each person who controls any Initial Purchaser within the meaning of either the Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or
several, to which they or any of them may become subject under the Act, the Exchange Act or other Federal, state or foreign statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions
in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a 
  

 18 

 
material fact contained in the Preliminary Memorandum or the Final Memorandum (or in any supplement or amendment thereto), or arise out of or are based upon
the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and agree to reimburse each
such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will
not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made in the Preliminary Memorandum, the
Final Memorandum, or in any amendment thereof or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by or on behalf of any of the Initial Purchasers for inclusion therein; and provided
further, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made
in the Preliminary Memorandum if copies of the Final Memorandum were timely delivered to the Initial Purchasers pursuant to Section 5 of this Agreement and a copy of the Final Memorandum (as then amended or supplemented if the Company shall have
furnished any amendments or supplements thereto) was not sent or given by or on behalf of the Initial Purchasers to the person asserting such loss, claim, damage or liability and if the Final Memorandum (as so amended or supplemented) would have
cured the defect giving rise to such loss, claim, damage or liability. This indemnity agreement will be in addition to any liability which the Company may otherwise have. 
  
 (b) Each Initial Purchaser severally and not jointly agrees to indemnify and hold harmless the Company, each of its
respective directors and officers and each person who controls the Company within the meaning of either the Act or the Exchange Act, to the same extent as the foregoing indemnity from the Company to each Initial Purchaser, but only with reference to
written information relating to the Initial Purchasers furnished to the Company by or on behalf of such Initial Purchaser through the Representatives specifically for inclusion in the Preliminary Memorandum or the Final Memorandum (or in any
amendment or supplement thereto). This indemnity agreement will be in addition to any liability that any Initial Purchaser may otherwise have. The Company acknowledges that (i) the statements set forth in the last paragraph of the cover page
regarding the delivery of the Securities and (ii) the disclosure in (x) the first sentence of the third paragraph, (y) the fourth, fifth and sixth sentences of the ninth paragraph and (z) the fifth and tenth paragraphs under the heading “Plan
of Distribution,” in each case in the Preliminary Memorandum and the Final Memorandum, constitute the only information furnished in writing by or on behalf of the Initial Purchasers for inclusion in the Preliminary Memorandum or the Final
Memorandum (or in any amendment or supplement thereto). 
  
 (c)
Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 8, notify the
indemni- 
  

 19 

 
fying party in writing of the commencement thereof; but the failure so to notify the indemnifying party (i) will not relieve it from liability under
paragraph (a) or (b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and defenses; and (ii) will not, in any event, relieve the
indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph (a) or (b) above. The indemnifying party shall be entitled to appoint counsel (including local counsel) of the
indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and
expenses of any separate counsel, other than local counsel if not appointed by the indemnifying party, retained by the indemnified party or parties except as set forth below); provided, however, that such counsel shall be reasonably
satisfactory to the indemnified party. Notwithstanding the indemnifying party’s election to appoint counsel (including local counsel) to represent the indemnified party in an action, the indemnified party shall have the right to employ separate
counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would present
such counsel with a conflict of interest; (ii) the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there
may be legal defenses available to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party; (iii) the indemnifying party shall not have employed counsel satisfactory to the indemnified
party to represent the indemnified party within a reasonable time after notice of the institution of such action; or (iv) the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying
party. An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect
of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes an unconditional release of each
indemnified party from all liability arising out of such claim, action, suit or proceeding. 
  
 (d) In the event that the indemnity provided in paragraph (a) or (b) of this Section 8 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company on the one hand and the
Initial Purchasers on the other agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending any loss, claim, damage, liability or
action) (collectively “Losses”) to which the Company and one or more of the Initial Purchasers may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the
Initial Purchasers on the other from the offering of the Securities; provided, however, that in no case shall any Initial Purchaser be responsible for any amount in excess of the purchase discount or commission applicable to the
Securities purchased by such Initial Purchaser hereunder. If the allocation provided by the 
  

 20 

 
immediately preceding sentence is unavailable for any reason, the Company and the Initial Purchasers severally shall contribute in such proportion as is
appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and of the Initial Purchasers on the other in connection with the statements or omissions which resulted in such Losses, as well as any
other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it, and benefits received by the Initial Purchasers shall be
deemed to be equal to the total purchase discounts and commissions. Relative fault shall be determined by reference to, among other things, whether any untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information provided by the Company on the one hand or the Initial Purchasers on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such
untrue statement or omission. The Company and the Initial Purchasers agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation that does not take account of the equitable
considerations referred to above. Notwithstanding the provisions of this paragraph (d), no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this Section 8, each person who controls an Initial Purchaser within the meaning of either the Act or the Exchange Act and each director, officer, employee, Affiliate and agent of an
Initial Purchaser shall have the same rights to contribution as such Initial Purchaser, and each person who controls the Company within the meaning of either the Act or the Exchange Act and each officer and director of the Company shall have the
same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph (d). 
  
 9. Default by an Initial Purchaser. If any one or more Initial Purchasers shall fail to purchase and pay for any of the Securities agreed to be
purchased by such Initial Purchaser hereunder and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Initial Purchasers shall be obligated severally to take up and
pay for (in the respective proportions which the amount of Securities set forth opposite their names in Schedule I hereto bears to the aggregate amount of Securities set forth opposite the names of all the remaining Initial Purchasers) the
Securities which the defaulting Initial Purchaser or Initial Purchasers agreed but failed to purchase; provided, however, that in the event that the aggregate principal amount of Securities which the defaulting Initial Purchaser or
Initial Purchasers agreed but failed to purchase shall exceed 10% of the aggregate amount of Securities set forth in Schedule I hereto, the remaining Initial Purchasers shall have the right to purchase all, but shall not be under any obligation to
purchase any, of the Securities, and if such nondefaulting Initial Purchasers do not purchase all the Securities, this Agreement will terminate without liability to any nondefaulting Initial Purchaser or the Company. In the event of a default by any
Initial Purchaser as set forth in this Section 9, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representatives shall determine in order that the required changes in the Final Memorandum or in any
other documents or arrangements may be effected. Nothing con- 
  

 21 

 
tained in this Agreement shall relieve any defaulting Initial Purchaser of its liability, if any, to the Company or any nondefaulting Initial Purchaser for
damages occasioned by its default hereunder. 
  
 10.
Termination. This Agreement shall be subject to termination in the absolute discretion of the Representatives, by notice given to the Company prior to delivery of and payment for the Securities, if at any time prior to such time (i) trading
in any of the Company’s securities shall have been suspended by the Commission or the Nasdaq National Market; (ii) trading in securities generally on the Nasdaq National Market shall have been suspended or limited or minimum prices shall have
been established on such Market; (iii) a banking moratorium shall have been declared either by U.S. federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities, declaration by the United States
of a national emergency or war or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Representatives, impractical or inadvisable to proceed with the offering or delivery of the
Securities as contemplated in the Final Memorandum (exclusive of any amendment or supplement thereto). 
  
 11. Representations and Indemnities to Survive. The respective agreements, representations, warranties, indemnities and other statements of the
Company or its respective officers or directors and of the Initial Purchasers set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Initial Purchasers or the
Company or any of their respective officers, directors or controlling persons referred to in Section 8 hereof, and will survive delivery of and payment for the Securities. The provisions of Sections 7 and 8 hereof shall survive the termination or
cancellation of this Agreement. 
  
 12. Notices. All
communications hereunder will be in writing and effective only on receipt, and, if sent to the Representatives, will be mailed, delivered or telefaxed to the Citigroup Global Markets Inc. General Counsel (fax no.: (212) 816-7912) and confirmed to
the General Counsel, Citigroup Global Markets Inc. at 388 Greenwich Street, New York, New York 10013, Attention: General Counsel; or, if sent to the Company, will be mailed, delivered or telefaxed to CV Therapeutics, Inc., 3172 Porter Drive, Palo
Alto, CA 94304, Attention: General Counsel (fax no.: 650-858-0388) and confirmed to it at Latham & Watkins LLP, 135 Commonwealth Drive, Menlo Park, California 94025, Attention: Alan C. Mendelson, Esq. (fax no. (650) 463-2600). 
  
 13. Successors. This Agreement will inure to the benefit of and be
binding upon the parties hereto and their respective successors and the indemnified officers and directors and controlling persons referred to in Section 8 hereof and their respective successors, and, except as expressly set forth in Section 5(g)
hereof, no other person will have any right or obligation hereunder. 
  
 14. Applicable Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be 
  

 22 

 
performed within the State of New York. The parties hereto each hereby waive any right to trial by jury in any action, proceeding or counterclaim arising out
of or relating to this Agreement. The Company hereby submits to the non-exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby. 
  
 15. Waiver of Tax
Confidentiality. Notwithstanding anything herein to the contrary, purchases of the Securities (and each employee, representative or other agent of the Company) may disclose to any and all persons, without limitation of any kind, the U.S. tax
treatment and U.S. tax structure of any transaction contemplated herein and all materials of any kind (including opinions or other tax analyses) that are provided to the purchasers of the Securities relating to such U.S. tax treatment and U.S. tax
structure, other than any information for which nondisclosure is reasonably necessary in order to comply with applicable securities law. 
  
 16. Counterparts. This Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together
shall constitute one and the same agreement. 
  
 17.
Headings. The section headings used herein are for convenience only and shall not affect the construction hereof. 
  
 18. Definitions. The terms that follow, when used in this Agreement, shall have the meanings indicated. 
  
 “Act” shall mean the Securities Act of 1933, as amended, and
the rules and regulations of the Commission promulgated thereunder. 
  
 “Affiliate” shall have the meaning specified in Rule 501(b) of Regulation D. 
  
 “Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking instiutions or trust
companies are authorized or obligated by law to close in the City of New York. 
  
 “Citigroup” shall mean Citigroup Global Markets Inc. 
  
 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
  
 “Commission” shall mean the Securities and Exchange Commission. 
  
 “Exchange Act” shall mean the Securities Exchange Act of
1934, as amended, and, where applicable, the rules and regulations of the Commission promulgated thereunder. 
  
 “Execution Time” shall mean, the date and time that this Agreement is executed and delivered by the parties hereto. 
  

 23 

 “Investment Company Act” shall mean the Investment Company Act of 1940, as amended, and,
where applicable, the rules and regulations of the Commission promulgated thereunder. 
  
 “NASD” shall mean the National Association of Securities Dealers, Inc. 
  
 “PORTAL” shall mean the Private Offerings, Resales and Trading through Automated Linkages system of the NASD. 
  
 “Regulation D” shall mean Regulation D under the Act.

  
 “Regulation S” shall mean Regulation S under
the Act. 
  
 “Trust Indenture Act” shall mean the
Trust Indenture Act of 1939, as amended, and, where applicable, the rules and regulations of the Commission promulgated thereunder. 
  
  

 24 

 If the foregoing is in accordance with your understanding of our agreement, please sign and return to us
the enclosed duplicate hereof, whereupon this Agreement and your acceptance shall represent a binding agreement between the Company and the several Initial Purchasers. 
  

	 Very truly yours,

	
	 CV THERAPEUTICS, INC.

		
	 By:
	 	 /s/    LOUIS G. LANGE, M.D., PH.D.

	 	 	 Name: Louis G. Lange, M.D., Ph.D.

	 	 	 Title: Chairman and Chief Executive Officer

  
  

 S-1 

	 The foregoing Agreement is hereby
 confirmed and accepted as of the
 date first above written.

	
	 CITIGROUP GLOBAL MARKETS INC.

		
	 By:
	 	 /s/    MARK SIMON

	 	 	Name: Mark Simon
	 	 	Title: Managing Director
	
	 For itself and the several Initial
 Purchasers named in Schedule I to
 the foregoing Agreement.

  
  

 S-2 

 SCHEDULE I 
  

	 Initial Purchasers

	  	 	  	 Principal Amount of
 Debentures
 to Be Purchased

	 Citigroup Global Markets Inc.
	  	US$	 	  	75,000,000
	 CIBC World Markets Corp.
	  	 	 	  	5,000,000
	 Deutsche Bank Securities Inc..
	  	 	 	  	5,000,000
	 First Albany Corporation
	  	 	 	  	5,000,000
	 Needham & Company, Inc.
	  	 	 	  	5,000,000
	 SC Cowen Securities Corporation
	  	 	 	  	5,000,000
			
	 Total
	  	US$	 	  	100,000,000
	 	  	 	 	  	

 EXHIBIT A 
  
 Selling Restrictions for Offers and 
 Sales Outside the United States 
  
 1. (a) The
Securities have not been and will not be registered under the Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in accordance with Regulation S under the Act or pursuant to an
exemption from the registration requirements of the Act. Each Initial Purchaser represents and agrees that, except as otherwise permitted by Section 4(a)(i) of the Agreement to which this is an exhibit, it has offered and sold the Securities, and
will offer and sell the Securities, (i) as part of their distribution at any time; and (ii) otherwise until one year after the later of the commencement of the offering and the Closing Date, only in accordance with Rule 903 of Regulation S under the
Act. Accordingly, each Initial Purchaser represents and agrees that neither it, nor any of its Affiliates nor any person acting on its or their behalf has engaged or will engage in any directed selling efforts with respect to the Securities, and
that it and they have complied and will comply with the offering restrictions requirement of Regulation S and will not engage in any hedging transactions involving the Securities except in compliance with the Act. Each Initial Purchaser agrees that,
at or prior to the confirmation of sale of Securities (other than a sale of Securities pursuant to Section 4(a)(i) of the Agreement to which this is an exhibit), it shall have sent to each distributor, dealer or person receiving a selling
concession, fee or other remuneration that purchases Securities from it during the distribution compliance period a confirmation or notice to substantially the following effect: 
  
 “The Securities covered hereby have not been registered under the U.S. Securities Act of 1933 (the
“Act”) and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or (ii) otherwise until one year after the later of the commencement
of the offering and June 18, 2003, except in either case in accordance with Regulation S or Rule 144A under the Act. Terms used above have the meanings given to them by Regulation S.” 
  
 (b) Each Initial Purchaser also represents and agrees that it has not entered
and will not enter into any contractual arrangement with any distributor with respect to the distribution of the Securities, except with its Affiliates or with the prior written consent of the Company. 
  
 (c) Terms used in this section have the meanings given to them by Regulation
S. 
  

 A-1 

 2. Each Initial Purchaser represents and agrees that it has (i) not offered or sold, and, prior to the
expiry of six months from the closing of the offering of the Securities will not offer or sell, any Securities to persons in the United Kingdom except to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of
investments, whether as principal or agent, for purposes of their businesses or otherwise in circumstances which have not resulted and will not result in an offer to the public in the United Kingdom within the meaning of the Public Offers of
Securities Regulations 1995, (ii) it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the
FSMA) received by it in connection with the issue or sale of the Securities in circumstances in which Section 21(1) of the Financial Services and Markets Act 2000 (the “FSMA”) does not apply to the Company, and (iii) it has complied
with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Securities in, from or otherwise involving the United Kingdom. 
  
 3. Each Initial Purchaser understands and acknowledges that no action has been or will be taken in any jurisdiction by the
Company that would permit a public offering of the securities, or possession or distribution of either Memorandum or any other offering or publicity material relating to the Securities, in any country or jurisdiction where action for that purpose is
required. 
  
 4. Each Initial Purchaser has complied and will
comply with all applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers Securities or has in its possession or distributes either Memorandum or any other offering or publicity material relating to the
Securities. 
  
  

 A-2 

 EXHIBIT B 
  
 Form of Opinion of Latham & Watkins LLP 
  
 1. The Company is a corporation under the DGCL, with corporate power and authority to own its properties and to conduct its business as described in the
Final Memorandum. Based on certificates from public officials, we confirm that the Company is validly existing and in good standing under the laws of the State of Delaware and is qualified to do business in the State of California. 
  
 2. The Purchase Agreement has been duly authorized by all necessary corporate
action on the part of the Company, and the Purchase Agreement has been duly executed and delivered by the Company. 
  
 3. The Indenture has been duly authorized by all necessary corporate action of the Company, and the Indenture has been duly executed and delivered by the
Company and is the legally valid and binding agreement of the Company, enforceable against the Company in accordance with its terms. 
  
 4. The Debentures have been duly authorized by all necessary corporate action of the Company and, when executed, issued and authenticated in accordance
with the terms of the Indenture and delivered to and paid for by you in accordance with the terms of the Purchase Agreement, will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their
terms. 
  
 5. The Shares have been duly authorized by all
necessary corporate action of the Company and the Shares, if any, issued upon due conversion of the Debentures in accordance with the terms of the Debentures and the Indenture would, if issued today, be validly issued, fully paid and nonassessable
and free of preemptive rights arising under the Company’s certificate of incorporation, bylaws or the DGCL. 
  
 6. The Registration Rights Agreement has been duly authorized by all necessary corporate action of the Company, and the Registration Rights Agreement has
been duly executed and delivered by the Company and is the legally valid and binding agreement of the Company, enforceable against the Company in accordance with its terms. 
  
 7. The Escrow Agreement has been duly authorized by all necessary corporate action of the Company, and the Escrow Agreement
has been duly executed and delivered by the Company and is the legally valid and binding agreement of the Company, enforceable against the Company in accordance with its terms. 
  

 B-1 

 8. The execution and delivery of the Purchase Agreement, the Indenture, the Registration Rights Agreement
and the Escrow Agreement, and the issuance and sale of the Debentures by the Company pursuant to the Purchase Agreement on the date hereof do not: 
  
 (i) violate the Company’s certificate of incorporation or bylaws; 
 (ii) violate the DGCL or any federal or California statute, rule or regulation applicable to the Company; or 
  
 (iii) require any consents, approvals or authorizations to
be obtained by the Company, or any registrations, declarations or filings to be made by the Company, in each case, under the DGCL or any federal or California statute, rule or regulation applicable to the Company, except such as may be required
under state securities laws in connection with the purchase and distribution of the Debentures by the Initial Purchasers. 
  
 9. Assuming that the representations, warranties and agreements of the Initial Purchasers contained in the Purchase Agreement are accurate and have been
complied with, no registration of the Debentures under the Securities Act of 1933, as amended (the “Securities Act”), and no qualification of the Indenture under the Trust Indenture Act of 1939, as amended, is required for the
purchase of the Debentures by you or the initial resale of the Debentures by you to “qualified institutional buyers” (as such term is defined under Rule 144A under the Securities Act) or in “offshore transactions” (as such term
is defined in Regulation S under the Securities Act), in each case, in the manner contemplated by the Purchase Agreement and the Final Memorandum. We express no opinion, however, as to when or under what circumstances any Debentures initially sold
by you may be reoffered or resold. 
  
 10. The statements in the
Final Memorandum under the captions “Description of Debentures” and “Description of Capital Stock,” insofar as they purport to constitute a summary of the legal matters or documents referred to therein, are accurate in all
material respects. 
  
 11. With your consent based solely on a
certificate of an officer of the Company as to factual matters, the Company is not an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 
  
 The primary purpose of our professional engagement was not to establish or confirm factual matters or financial or
quantitative information. Therefore, we are not passing upon and do not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Final Memorandum, (except to the extent expressly set forth in the
numbered paragraph 10 of our opinion letter to you of even date), and have not made an independent check or verification thereof (except as aforesaid). However, in the course of acting 
  

 B-2 

 
as counsel to the Company in connection with the preparation by the Company of the Final Memorandum, we reviewed the Final Memorandum, and participated in
conferences and telephone conversations with officers and other representatives of the Company, the independent public accountants for the Company, your representatives, and your counsel, during which conferences and conversations the contents of
the Final Memorandum and related matters were discussed. We also reviewed and relied upon certain corporate records and documents and oral and written statements of officers and other representatives of the Company and others as to the existence and
consequence of certain factual and other matters. 
  
 Based on our
participation, review and reliance as described above, we advise you that no facts came to our attention that caused us to believe that the Final Memorandum, as of its date or as of the date hereof, contained or contains an untrue statement of a
material fact or omitted or omits to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; it being understood that we express no belief with respect to the
financial statements, schedules, or other financial data included or incorporated by reference in, or omitted from, the Final Memorandum. 
  
  

 B-3 

 EXHIBIT C 
  
 Form of Opinion of Tricia Suvari General Counsel for the Company 
  
 1. The issuance and sale of the Securities by the Company pursuant to the Purchase Agreement will not result in the breach
of or any default under any indentures, notes, loan agreements, mortgages, deeds of trust, security agreements and other written agreements and instruments creating, evidencing or securing indebtedness of the Company for borrowed money that are
listed as exhibits to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2002 or the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2003 (collectively, the “Material
Agreements”). 
  
 2. To the best of my knowledge, the Company
(i) is not in violation of its certificate of incorporation or bylaws, (ii) is not in default, and no event has occurred, which, with notice or lapse of time or both, would constitute a default, in the due performance or observance of any term,
covenant or condition contained in any of the Material Agreements, and (iii) is not in violation of any law, ordinance, governmental rule, regulation or court decree to which it or its property or assets may be subject and has obtained such
licenses, permits, certificates, franchises or other governmental authorizations or permits necessary to the ownership of its property or to the conduct of its business, except, in the case of clauses (ii) and (iii), for those defaults, violations
or failures which, either individually or in the aggregate, would not have a material adverse effect on the condition (financial or otherwise), results of operations, business or prospects of the Company. 
  
 3. To the best of my knowledge, there are no legal or governmental
proceedings involving the Company required to be described in the Final Memorandum that are not described as required. 
  
 4. The statements in or incorporated by reference in the Final Memorandum, insofar as such statements purport to describe or summarize applicable
provisions of the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder, are accurate and complete in all material respects and fairly present the information set forth therein. 
  
 5. The Company has obtained such licenses, permits, approvals, and
authorizations required by the FDA that are necessary for the conduct of the business of the Company as it is currently conducted and described in the Final Memorandum and to my knowledge such authorizations are in effect. 
  
 6. I am not aware of any lawsuit or regulatory proceeding, pending or
threatened, brought by or before the FDA, in which the Company is or would be the defen- 
  

 C-1 

 
dant or respondent, nor am I aware of any adverse judgment, decree or order currently in effect that has been issued by the FDA against the Company

  
  

 C-2 

 EXHIBIT D 
  
 [Form of Lock-Up Agreement] 
  
 [            ], 2003 
  
 CITIGROUP GLOBAL MARKETS INC. 
 As Representative of the 
 Several Initial Purchasers 
 named in Schedule I to 
 the Purchase Agreement referred to below 
 388 Greenwich Street 
 New York, New York 10013 
  

	 Re:
	  	CV Therapeutics, Inc. - Senior Subordinated
	 	  	Convertible Debenture Offering 

  
 Ladies and Gentlemen: 
  
 The undersigned understands that you, as Representative of the Initial
Purchasers, propose to enter into a Purchase Agreement (the “Purchase Agreement”) with CV Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the offering (the “Offering”) by
the Initial Purchasers to be named in Schedule I to the Purchase Agreement (the “Initial Purchasers”), of Senior Subordinated Convertible Debentures due 2023 (the “Securities”) convertible into common stock, par
value $.001 per share (the “Common Stock”) of the Company. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Purchase Agreement. 
  
 In consideration of the Initial Purchasers’ agreement to purchase the
Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Citigroup Global Markets Inc. on behalf of the Initial Purchasers, which
shall not be unreasonably withheld, the undersigned will not, during the period ending 90 days after the date of the final offering memorandum relating to the Offering (the “Final Memorandum”), (1) offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of
Common Stock of the Company or any securities convertible into or exercisable or exchangeable for Common Stock (including, but not limited to, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules
and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) other than as a bona fide gift or bona fide gifts, provided, however, that the recipient of such
bona fide gift or 
  

 D-1 

 
bona fide gifts shall execute a copy of and be bound by the terms of, this Agreement, or (2) enter into any swap, option, future, forward or other agreement
that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock, including, but not limited to, any security convertible into or exercisable or exchangeable for Common Stock, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. In addition, the undersigned agrees that, without the prior written consent of Citigroup Global Markets Inc. on behalf
of the Initial Purchasers, which shall not be unreasonably withheld, it will not, during the period ending 90 days after the date of the Final Memorandum, make any demand for or exercise any right with respect to, the registration of any shares of
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. 
  
 The foregoing paragraph shall not apply to the sale or other transfer of up to an aggregate of 300,000 shares of Common Stock held by officers and directors of the Company signing a lock-up agreement in connection
with the Offering, the allocation of such shares among such officers and directors to be determined by the Company in its sole discretion. 
  
 In furtherance of the foregoing, the Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are
hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. 
  
 The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority
herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. 
  
 The undersigned understands that, if the Purchase Agreement (other than the provisions thereof which survive termination)
shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, this Lock-Up Agreement shall terminate and be of no further force or effect, and the undersigned shall be released from all obligations under
this Lock-Up Agreement. 
  
 The undersigned understands that the
Initial Purchasers propose to enter into the Purchase Agreement and to proceed with the Offering in reliance upon this Lock-Up Agreement. 
  

 D-2 

 THIS LOCK-UP AGREEMENT SHALL BE GOVERNED BY AND 
 CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 
  

	 Very truly yours,

		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

  

	 Accepted as of the date
 first set forth above:

	
	 CITIGROUP GLOBAL MARKETS INC.

	 	 	 Acting on behalf of itself and the other Initial
 Purchasers to be named in Schedule I to the
 Purchase Agreement

		
	 By:
	 	 CITIGROUP GLOBAL MARKETS INC.

		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

  
  
  
  
  
  

 D-3Registration Rights Agreement, dated as of June 18, 2003

 Exhibit 10.67 
  
 REGISTRATION RIGHTS AGREEMENT 
  
 among 
  
 CV THERAPEUTICS, INC., 
  
 CITIGROUP GLOBAL MARKETS INC., 
 CIBC
WORLD MARKETS CORP., DEUTSCHE BANK SECURITIES INC., FIRST 
 ALBANY CORPORATION, NEEDHAM & COMPANY, INC. and SG COWEN

 SECURITIES CORPORATION 
  
 Dated June 18, 2003 
  
 Registration Rights Agreement (this “Agreement”), dated as of June 18, 2003, among CV Therapeutics, Inc., a Delaware corporation
(together with any successor entity, the “Issuer”), Citigroup Global Markets Inc. (“Citigroup”), CIBC World Markets Corp., Deutsche Bank Securities Inc., First Albany Corporation, Needham & Company, Inc. and SG
Cowen Securities Corporation (collectively, the “Initial Purchasers”). 
  
 Pursuant to the Purchase Agreement, dated June 13, 2003, between the Issuer and the Initial Purchasers (the “Purchase Agreement”), the Initial Purchasers have agreed to purchase from the Issuer up to
$100,000,000 ($125,000,000 if the Initial Purchasers’ option is exercised in full) in aggregate principal amount of 2.0% Senior Subordinated Convertible Debentures due 2023 (the “Debentures”). The Debentures will be convertible
into fully paid, nonassessable shares of common stock, par value $.001 per share, of the Issuer (the “Common Stock”) on the terms, and subject to the conditions, set forth in the Indenture (as defined herein). To induce the Initial
Purchasers to purchase the Debentures, the Issuer has agreed to provide the registration rights set forth in this Agreement pursuant to the Purchase Agreement. 
  

The parties hereby agree as follows: 
  
 1. Definitions. As used in this Agreement, the following capitalized terms shall have the following meanings: 
  
 Advice: As defined in Section 4(c)(ii) hereof. 
  
 Agreement: As defined in the preamble hereto. 
  
 Business Day: A day other than a Saturday or Sunday or any federal
holiday in the United States. 
  
 Citigroup: As defined in
the preamble hereto. 
  
 Commission: Securities and
Exchange Commission. 
  
 Common Stock: As defined in the
preamble hereto. 

 Damages Payment Date: Each Interest Payment Date. For purposes of this Agreement, if no Debentures
are outstanding, “Damages Payment Date” shall mean each May 16 and November 16. 
  
 Debentures: As defined in the preamble hereto. 
  
 Effectiveness Period: As defined in Section 2(a)(iii) hereof. 
  
 Effectiveness Target Date: As defined in Section 2(a)(ii) hereof. 
  
 Exchange Act: Securities Exchange Act of 1934, as amended. 
  
 Holder: A Person who owns, beneficially or otherwise, Transfer
Restricted Securities. 
  
 Indenture: The Indenture, dated
as of June 18, 2003, between the Issuer and Wells Fargo Bank Minnesota, N.A., as trustee, pursuant to which the Debentures are to be issued, as such Indenture is amended, modified or supplemented from time to time in accordance with the terms
thereof. 
  
 Initial Purchasers: As defined in the preamble
hereto. 
  
 Interest Payment Date: As defined in the
Indenture. 
  
 Issuer: As defined in the preamble hereto.

  
 Liquidated Damages: As defined in Section 3(a) hereof.

  
 Majority of Holders: Holders holding over 50% of the
aggregate principal amount of Debentures outstanding; provided, however, that, for purpose of this definition, a holder of shares of Common Stock which constitute Transfer Restricted Securities and were issued upon conversion of the
Debentures shall be deemed to hold an aggregate principal amount of Debentures (in addition to the aggregate principal amount of Debentures held by such holder) equal to the aggregate principal amount of Debentures converted by such Holder into such
shares of Common Stock. 
  
 NASD: National Association of
Securities Dealers, Inc. 
  
 Person: An individual,
partnership, corporation, unincorporated organization, trust, joint venture or a government or agency or political subdivision thereof. 
  
 Prospectus: The prospectus included in a Shelf Registration Statement, as amended or supplemented by any prospectus supplement and by all other
amendments thereto, including post-effective amendments, and all material incorporated by reference into such Prospectus. 
  
 Purchase Agreement: As defined in the preamble hereto. 
  

 2 

 Questionnaire Deadline: As defined in Section 2(b) hereof. 
  
 Record Holder: With respect to any Damages Payment Date, each Person
who is a Holder on the record date with respect to the Interest Payment Date on which such Damages Payment Date shall occur. In the case of a Holder of shares of Common Stock issued upon conversion of the Debentures, “Record Holder” shall
mean each Person who is a Holder of shares of Common Stock which constitute Transfer Restricted Securities on the May 2 or November 2 immediately preceding the Damages Payment Date. 
  
 Registration Default: As defined in Section 3(a) hereof. 
  
 Sale Notice: As defined in Section 4(e) hereof. 
  
 Securities Act: Securities Act of 1933, as amended. 
  
 Shelf Filing Deadline: As defined in Section 2(a)(i) hereof.

  
 Shelf Registration Statement: As defined in Section
2(a)(i) hereof. 
  
 Suspension Period: As defined in
Section 4(b)(i) hereof. 
  
 TIA: Trust Indenture Act of
1939, as in effect on the date the Indenture is qualified under the TIA. 
  
 Transfer Restricted Securities: Each Debenture and each share of Common Stock issued upon conversion of Debentures until the earlier of: 
  
 (i) the date on which such Debenture or such share of Common Stock issued upon conversion has been
effectively registered under the Securities Act and disposed of in accordance with the Shelf Registration Statement; 
  
 (ii) the date on which such Debenture or such share of Common Stock issued upon conversion is transferred in compliance with Rule 144
under the Securities Act or may be sold or transferred pursuant to Rule 144(k) under the Securities Act (or any other similar provision then in force); or 
  
 (iii) the date on which such Debenture or such share of Common Stock issued upon conversion ceases to be outstanding (whether as a result
of redemption, repurchase and cancellation, conversion or otherwise). 
  
 Underwritten Registration or Underwritten Offering: A registration in which securities of the Issuer are sold to an underwriter for reoffering to the public. 
  

 3 

 2. Shelf Registration. 
  
 (a) The Issuer shall: 
  
 (i) not later than 120 days after the date hereof (the “Shelf Filing Deadline”), cause to be filed a registration
statement pursuant to Rule 415 under the Securities Act (the “Shelf Registration Statement”), which Shelf Registration Statement shall provide for resales of all Transfer Restricted Securities held by Holders that have provided the
information required pursuant to the terms of Section 2(b) hereof; 
  
 (ii) use its best efforts to cause the Shelf Registration Statement to be declared effective by the Commission as promptly as practicable, but in no event later than 210 days after the date hereof (the
“Effectiveness Target Date”); and 
  
 (iii) use its best efforts to keep the Shelf Registration Statement continuously effective, supplemented and amended as required by the provisions of Section 4(b) hereof to the extent necessary to ensure that (A) it is available for resales
by the Holders of Transfer Restricted Securities entitled to the benefit of this Agreement and (B) conforms with the requirements of this Agreement and the Securities Act and the rules and regulations of the Commission promulgated thereunder as
announced from time to time for a period (the “Effectiveness Period”) of: 
  
 (1) two years following the last date of original issuance of Debentures; or 
  
 (2) such shorter period that will terminate when (x) all of the Holders of Transfer Restricted Securities are able to sell all Transfer Restricted
Securities immediately without restriction pursuant to Rule 144(k) under the Securities Act or any successor rule thereto, (y) when all Transfer Restricted Securities have ceased to be outstanding (whether as a result of redemption, repurchase and
cancellation, conversion or otherwise) or (z) all Transfer Restricted Securities registered under the Shelf Registration Statement have been sold. 
  
 (b) No Holder may include any of its Transfer Restricted Securities in the Shelf Registration Statement pursuant to this Agreement unless such Holder
furnishes to the Issuer in writing, prior to or on the 20th Business Day after receipt of a request therefor (the
“Questionnaire Deadline”), such information as the Issuer may reasonably request, including the information specified in the form of questionnaire attached hereto as Exhibit A, for use in connection with the Shelf
Registration Statement or the Prospectus or preliminary Prospectus included therein and in any application to be filed with or under state securities laws. 
  
 In connection with all such requests for information from Holders in addition to that set forth in Exhibit A, the Issuer shall notify such Holders
of the requirements set forth in the preceding sentence. No Holder shall be entitled to Liquidated Damages pursuant to Section 3 hereof unless such Holder shall have provided all such requested information prior to or on the Questionnaire Deadline.

  

 4 

 3. Liquidated Damages. 
  
 (a) If: 
  
 (i) the Shelf Registration Statement is not filed with the Commission prior to or on the Shelf Filing Deadline; 
  
 (ii) the Shelf Registration Statement has not been declared
effective by the Commission prior to or on the Effectiveness Target Date; 
  
 (iii) subject to the provisions of Section 4(b)(i) hereof, the Shelf Registration Statement is filed and declared effective but, during the Effectiveness Period, shall thereafter cease to be effective or fail to be
usable for its intended purpose without being succeeded within five Business Days by a post-effective amendment to the Shelf Registration Statement or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act that cures such failure and, in the case of a post-effective amendment, is itself immediately declared effective; or 
  
 (iv) prior to or on the 45th or 60th day, as the case may be, of any Suspension Period, such suspension has not been
terminated 
  
 (each such event referred to in foregoing clauses (i) through (iv),
a “Registration Default”), the Issuer hereby agrees to pay liquidated damages (“Liquidated Damages”) with respect to the Transfer Restricted Securities from and including the day following the Registration Default
to but excluding the day on which the Registration Default has been cured: 
  
 (A) in respect of the Debentures, to each holder of Debentures, (x) with respect to the first 90-day period during which a Registration Default shall have occurred and be continuing, in an amount per year equal to an
additional 0.25% of the principal amount of the Debentures and (y) with respect to the period commencing on the 91st
day following the day the Registration Default shall have occurred and be continuing, in an amount per year equal to an additional 0.50% of the principal amount of the Debentures; provided that in no event shall Liquidated Damages accrue at a rate
per year exceeding 0.50% of the principal amount of the Debentures; and 
  
 (B) In respect of any shares of Common Stock, to each holder of shares of Common Stock issued upon conversion of Debentures, (x) with respect to the first 90-day period in which a Registration Default shall have
occurred and be continuing, in an amount per year equal to 0.25% of the principal amount of the converted Debentures and (y) with respect to the period commencing the 91st day following the day the Registration Default shall have occurred and be continuing, in an amount per year equal to 0.50% of the principal amount of the
converted Debentures; provided, however, that in no event shall Liquidated Damages accrue at a rate per year exceeding 0.50% of the principal amount of the converted Debentures. 
  

 5 

 (b) All accrued Liquidated Damages shall be paid in arrears to Record Holders by the Issuer on each
Damages Payment Date by wire transfer of immediately available funds or by federal funds check. Following the cure of all Registration Defaults relating to any particular Debenture or share of Common Stock, the accrual of Liquidated Damages with
respect to such Debenture or share of Common Stock will cease. 
  
 All obligations of the Issuer set forth in this Section 3 that are outstanding with respect to any Transfer Restricted Security at the time such security ceases to be a Transfer Restricted Security shall survive until such time as all such
obligations with respect to such Transfer Restricted Security shall have been satisfied in full. 
  
 The Liquidated Damages set forth above shall be the exclusive monetary remedy available to the Holders for such Registration Default. 
  
 4. Registration Procedures. 
  
 (a) In connection with the Shelf Registration Statement, the Issuer shall
comply with all the provisions of Section 4(b) hereof and shall use its best efforts to effect such registration to permit the resale of the Transfer Restricted Securities in accordance with the intended method or methods of distribution thereof,
and pursuant thereto, shall as expeditiously as possible prepare and file with the Commission a Shelf Registration Statement relating to registration on any appropriate form under the Securities Act. 
  
 (b) In connection with the Shelf Registration Statement and any Prospectus
required by this Agreement to permit the resale of Transfer Restricted Securities, the Issuer shall: 
  
 (i) Subject to any notice by the Issuer in accordance with this Section 4(b) of the existence of any fact or event of the kind described
in Section 4(b)(iii)(D), use its best efforts to keep the Shelf Registration Statement continuously effective during the Effectiveness Period. Upon the occurrence of any event that would cause the Shelf Registration Statement or the Prospectus
contained therein (A) to contain a material misstatement or omission or (B) not be effective and usable for resale of Transfer Restricted Securities during the Effectiveness Period, the Issuer shall file promptly an appropriate amendment to the
Shelf Registration Statement or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, in the case of clause (A), correcting any such misstatement or omission, and, in the case of either clause (A) or
(B), use its best efforts to cause any such amendment to be declared effective and the Shelf Registration Statement and the related Prospectus to become usable for their intended purposes as soon as practicable thereafter. Notwithstanding the
foregoing, the Issuer may suspend the effectiveness of the Shelf Registration Statement by written notice to the Holders for a period not to exceed an aggregate of 45 days in any 90-day period (each such period, a “Suspension
Period”) if: 
  
 (x) an event occurs and
is continuing as a result of which the Shelf Registration Statement would, in the Issuer’s reasonable judgment, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading; and 
  

 6 

 (y) the Issuer reasonably determines that the disclosure of such event at such time would
have a material adverse effect on the business of the Issuer (and its subsidiaries, if any, taken as a whole); provided, however, that in the event the disclosure relates to a previously undisclosed proposed or pending material
business transaction, the disclosure of which would impede the Issuer’s ability to consummate such transaction, the Issuer may extend a Suspension Period from 45 days to 60 days; and provided further, that Suspension Periods shall
not exceed an aggregate of 90 days in any 360-day period. 
  
 (ii) Prepare and file with the Commission such post-effective amendments to the Shelf Registration Statement as may be necessary to keep the Shelf Registration Statement effective during the Effectiveness Period;
cause the Prospectus to be supplemented by any required Prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Securities Act, and to comply fully with the applicable provisions of Rules 424 and 430A under the
Securities Act in a timely manner; and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by the Shelf Registration Statement during the applicable period in accordance with the intended method
or methods of distribution by the sellers thereof set forth in the Shelf Registration Statement or Prospectus supplement. 
  
 (iii) Advise the selling Holders that have provided the information required by Section 4(d) of this Agreement, Citigroup, as
representative of the Initial Purchasers, and the underwriter(s), if any, promptly (but in any event within five Business Days) and, if requested by such Persons, confirm such advice in writing: 
  
 (A) with respect to the Shelf Registration Statement or any
post-effective amendment thereto, when the same has become effective, and when the Prospectus or any Prospectus supplement or post-effective amendment has been filed, 
  
 (B) of any request by the Commission for amendments to the Shelf Registration Statement or amendments or
supplements to the Prospectus or for additional information relating thereto, 
  
 (C) of the issuance by the Commission of any stop order suspending the effectiveness of the Shelf Registration Statement under the Securities Act or of the suspension by any state securities commission of the
qualification of the Transfer Restricted Securities for offering or sale in any jurisdiction, or the initiation of any proceeding for any of the preceding purposes, or 
  
 (D) of the existence of any fact or the happening of any event, during the Effectiveness Period, that makes
any statement of a material fact made in the Shelf Registration Statement or the Prospectus, any amendment or supplement thereto, or any document incorporated by reference therein untrue, or that requires the making of any additions to or changes in
the Shelf Registration Statement or the Prospectus in order to make the statements therein not misleading. 
  

 7 

 If at any time the Commission shall issue any stop order suspending the effectiveness of the Shelf
Registration Statement, or any state securities commission or other regulatory authority shall issue an order suspending the qualification or exemption from qualification of the Transfer Restricted Securities under state securities or Blue Sky laws,
the Issuer shall use its reasonable best efforts to obtain the withdrawal or lifting of such order at the earliest possible time. 
  
 (iv) Furnish to each of the selling Holders that have provided the information required by Section 4(d) of this Agreement, Citigroup, as
representative of the Initial Purchasers and each of the underwriter(s), if any, before filing with the Commission, a copy of the Shelf Registration Statement and copies of any Prospectus included therein or any amendments or supplements to the
Shelf Registration Statement or Prospectus (other than documents incorporated by reference after the initial filing of the Shelf Registration Statement), which documents will be subject to the review of such Holders, Citigroup as representative of
the Initial Purchasers and underwriter(s), if any, for a period of at least ten Business Days, and the Issuer will not file any Shelf Registration Statement or Prospectus or any amendment or supplement to the Shelf Registration Statement or
Prospectus (other than documents incorporated by reference) to which a selling Holder of Transfer Restricted Securities covered by the Shelf Registration Statement, Citigroup, as representative of the Initial Purchasers, or the underwriter(s), if
any, shall reasonably object within five Business Days after the receipt thereof. A selling Holder, Citigroup, as representative of the Initial Purchasers, or underwriter, if any, shall be deemed to have reasonably objected to such filing if the
Shelf Registration Statement, amendment, Prospectus or supplement, as applicable, as proposed to be filed, contains a material misstatement or omission. Notwithstanding the foregoing, the Issuer shall not be required to furnish the selling Holders
with any amendment or supplement to the Shelf Registration Statement or Prospectus filed solely to reflect changes to the amount of Debentures held by any particular Holder at the request of such Holder or immaterial revisions to the information
contained therein. 
  
 (v) If the selling Holders
propose to make an underwritten public offering of the Transfer Restricted Securities, make available at reasonable times for inspection by one or more representatives of the selling Holders, designated in writing by a Majority of Holders whose
Transfer Restricted Securities are included in the Shelf Registration Statement, any underwriter participating in any distribution pursuant to the Shelf Registration Statement and any attorney or accountant retained by such selling Holders or any of
the underwriter(s), all financial and other records, pertinent corporate documents and properties of the Issuer as shall be reasonably necessary to enable them to exercise any applicable due diligence responsibilities, and cause the Issuer’s
officers, directors, managers and employees to supply all information reasonably requested by any such representative or representatives of the selling Holders, underwriter, attorney or accountant in connection with the Shelf Registration Statement
after the filing thereof and before its effectiveness; provided, however, that any information designated by the Issuer as confidential at the time of delivery of such information shall be kept confidential by the recipient thereof.

  

 8 

 (vi) If requested by any selling Holders, Citigroup, as representative of the Initial
Purchasers, or the underwriter(s), if any, promptly incorporate in the Shelf Registration Statement or Prospectus, pursuant to a supplement or post-effective amendment if necessary, such information as such selling Holders, Citigroup, as
representative of the Initial Purchasers, and such underwriter(s), if any, may reasonably request to have included therein, including, without limitation: (1)information relating to the “Plan of Distribution” of the Transfer Restricted
Securities, (2) information with respect to the principal amount of Debentures or number of shares of Common Stock being sold to such underwriter(s), (3) the purchase price being paid therefor and (4) any other terms of the offering of the Transfer
Restricted Securities to be sold in such offering; and make all required filings of such Prospectus supplement or post-effective amendment as soon as reasonably practicable after the Issuer is notified of the matters to be incorporated in such
Prospectus supplement or post-effective amendment. Notwithstanding the foregoing, following the effective date of the Shelf Registration Statement, the Issuer shall not be required to file more than one such supplement or post-effective amendment to
reflect changes in the amount of Debentures held by any particular Holder at the request of such Holder in any 30-day period. 
  
 (vii) Furnish to each selling Holder, Citigroup, as representative of the Initial Purchasers, and each of the underwriter(s), if any,
without charge, at least one copy of the Shelf Registration Statement, as first filed with the Commission, and of each amendment thereto (and any documents incorporated by reference therein or exhibits thereto (or exhibits incorporated in such
exhibits by reference) as such Person may request). 
  
 (viii) Deliver to each selling Holder, Citigroup, as representative of the Initial Purchasers, and each of the underwriter(s), if any, without charge, as many copies of the Prospectus (including each preliminary prospectus) and any
amendment or supplement thereto as such Persons reasonably may request; subject to any notice by the Issuer in accordance with this Section 4(b) of the existence of any fact or event of the kind described in Section 4(b)(iii)(D), the Issuer hereby
consents to the use of the Prospectus and any amendment or supplement thereto by each of the selling Holders and each of the underwriter(s), if any, in connection with the offering and the sale of the Transfer Restricted Securities covered by the
Prospectus or any amendment or supplement thereto. 
  
 (ix) If an underwriting agreement is entered into and the registration is an Underwritten Registration, the Issuer shall: 
  
 (A) upon request, furnish to each selling Holder and the underwriter(s), if any, in such substance and scope as they may reasonably
request and as are customarily made by issuers to underwriters in primary underwritten offerings, upon the date of closing of any sale of Transfer Restricted Securities in an Underwritten Registration: (1) a certificate, dated the date of such
closing, signed by the Chief Financial Officer of the Issuer confirming, as of the date thereof, the matters set forth in Section 6(d) of the Purchase Agreement and such other matters as such parties may reasonably request; (2) opinions, each dated
the date of such closing, of counsel to the Issuer covering such of the matters set forth in the exhibits to the 
  

 9 

 
Purchase Agreement referred to in Section 6(a) and 6(b) thereof as are customarily covered in legal opinions to underwriters in connection with primary
underwritten offerings of securities; and (3) customary comfort letters, dated the date of such closing, from the Issuer’s independent certified public accountants (and from any other accountants whose report is contained or incorporated by
reference in the Shelf Registration Statement), in the customary form and covering matters of the type customarily covered in comfort letters to underwriters in connection with primary underwritten offerings of securities; 
  
 (B) set forth in full in the underwriting agreement, if any,
indemnification provisions and procedures which provide rights no less protective than those set forth in Section 6 hereof with respect to all parties to be indemnified; and 
  
 (C) deliver such other documents and certificates as may be reasonably requested by such parties to evidence
compliance with clause (A) above and with any customary conditions contained in the underwriting agreement or other agreement entered into by the selling Holders pursuant to this clause (ix). 
  
 (x) Before any public offering of Transfer Restricted
Securities, cooperate with the selling Holders, the underwriter(s), if any, and their respective counsel in connection with the registration and qualification of the Transfer Restricted Securities under the securities or Blue Sky laws of such
jurisdictions as the selling Holders or underwriter(s), if any, may reasonably request and do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Transfer Restricted Securities covered by
the Shelf Registration Statement; provided, however, that the Issuer shall not be required (A) to register or qualify as a foreign corporation or a dealer of securities where it is not now so qualified or to take any action that would
subject it to the service of process in any jurisdiction where it is not now so subject or (B) to subject itself to taxation in any such jurisdiction if they are not now so subject. 
  
 (xi) Cooperate with the selling Holders and the underwriter(s), if any, to facilitate the timely preparation
and delivery of certificates representing Transfer Restricted Securities to be sold and, when issued to the purchasers of Transfer Restricted Securities pursuant to the Shelf Registration Statement, not bearing any restrictive legends (unless
required by applicable securities laws); and enable such Transfer Restricted Securities to be in such denominations and registered in such names as the selling Holders or the underwriter(s), if any, may request at least two Business Days before any
sale of Transfer Restricted Securities made by the selling Holders or such underwriter(s). 
  
 (xii) Use its best efforts to cause the Transfer Restricted Securities covered by the Shelf Registration Statement to be registered with
or approved by such other U.S. governmental agencies or authorities as may be necessary to enable the seller or sellers thereof or the underwriter(s), if any, to consummate the disposition of such Transfer Restricted Securities. 
  
 (xiii) Subject to Section 4(b)(i) hereof, if any fact or
event contemplated by Section 4(b)(iii)(D) hereof shall exist or have occurred, use its reasonable best efforts to pre- 
  

 10 

 
pare a supplement or post-effective amendment to the Shelf Registration Statement or related Prospectus or any document incorporated therein by reference or
file any other required document so that, as thereafter delivered to the purchasers of Transfer Restricted Securities, the Prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading. 
  
 (xiv) Provide CUSIP numbers for all Transfer Restricted Securities not later than the effective date of the Shelf Registration Statement and provide the Trustee under the Indenture with certificates for the Debentures
that are in a form eligible for deposit with The Depository Trust Company. 
  
 (xv) Cooperate with respect to any filings required to be made with the NASD and in the performance of any due diligence investigation by any underwriter that is required to be retained in accordance with the rules
and regulations of the NASD. 
  
 (xvi) Otherwise
use its best efforts to comply with all applicable rules and regulations of the Commission and all reporting requirements under the rules and regulations of the Exchange Act. 
  
 (xvii) Cause the Indenture to be qualified under the TIA not later than the effective date of the Shelf
Registration Statement required by this Agreement, and, in connection therewith, cooperate with the Trustee and the holders of Debentures to effect such changes to the Indenture as may be required for such Indenture to be so qualified in accordance
with the terms of the TIA; and execute and use its best efforts to cause the Trustee thereunder to execute all documents that may be required to effect such changes and all other forms and documents required to be filed with the Commission to enable
such Indenture to be so qualified in a timely manner. 
  
 (xviii) Cause all Transfer Restricted Securities covered by the Shelf Registration Statement to be listed or quoted, as the case may be, on each securities exchange or automated quotation system on which similar securities issued by the
Issuer are then listed or quoted. 
  
 (xix) Make
available to each Holder upon written request each document filed with the Commission pursuant to the requirements of Section 13 and Section 15 of the Exchange Act after the effective date of the Shelf Registration Statement. 
  
 (xx) If requested by the underwriters, make appropriate
officers of the Issuer available to the underwriters for meetings with prospective purchasers of the Transfer Restricted Securities and prepare and present to potential investors customary “road show” material in a manner consistent with
new issuances of other securities similar to the Transfer Restricted Securities. 
  
 (xxi) Use its best efforts to obtain a waiver from each person who would otherwise have the right to have securities of the Issuer (other
than Transfer Restricted Securities) registered on the Shelf Registration Statement required by this Agreement. To the 
  

 11 

 
extent the Issuer does not receive such waivers, it will use its best efforts to obtain the consent of such persons from whom waivers are not obtained to
file a separate registration statement with respect to all such other registrable securities, rather than include them in the Shelf Registration Statement and, upon receipt of such consent, to register such registrable securities in accordance
therewith. 
  
 (c) Each Holder agrees by acquisition of a
Transfer Restricted Security that, upon receipt of any notice from the Issuer of the existence of any fact of the kind described in Section 4(b)(iii)(D) hereof, such Holder will, and will use its reasonable best efforts to cause any underwriter(s)
in an Underwritten Offering to, forthwith discontinue disposition of Transfer Restricted Securities pursuant to the Shelf Registration Statement until: 
  
 (i) such Holder has received copies of the supplemented or amended Prospectus contemplated by Section 4(b)(xiii) hereof; or 
  
 (ii) such Holder is advised in writing (the
“Advice”) by the Issuer that the use of the Prospectus may be resumed, and has received copies of any additional or supplemental filings that are incorporated by reference in the Prospectus. If so directed by the Issuer, each Holder
will deliver to the Issuer (at the Issuer’s expense) all copies, other than permanent file copies then in such Holder’s possession, of the Prospectus covering such Transfer Restricted Securities that was current at the time of receipt of
such notice of suspension. 
  
 (d) Each Holder who intends to be
named as a selling Holder in the Shelf Registration Statement shall furnish to the Issuer in writing, prior to or on the 20th Business Day after receipt of a request therefor as set forth in a questionnaire, such information regarding such Holder and the proposed distribution by such Holder of its Transfer Restricted Securities as the Issuer may reasonably
request for use in connection with the Shelf Registration Statement or Prospectus or preliminary Prospectus included therein. (The form of the questionnaire is attached hereto as Exhibit A.) Holders that do not complete the questionnaire and
deliver it to the Issuer shall not be named as selling securityholders in the Prospectus or preliminary Prospectus included in the Shelf Registration Statement and therefore shall not be permitted to sell any Transfer Restricted Securities pursuant
to the Shelf Registration Statement. Each Holder who intends to be named as a selling Holder in the Shelf Registration Statement shall promptly furnish to the Issuer in writing such other information as the Issuer may from time to time reasonably
request in writing. Each Holder as to which the Shelf Registration Statement is being effected agrees to furnish promptly to the Issuer all information required to be disclosed in order to make information previously furnished to the Issuer by such
Holder not materially misleading. 
  
 (e) Upon the effectiveness
of the Shelf Registration Statement, each Holder shall notify the Issuer at least three Business Days prior to any intended distribution of Transfer Restricted Securities pursuant to the Shelf Registration Statement (a “Sale
Notice”), which Sale Notice shall be effective for five Business Days. Each Holder of this Security, by accepting the same, agrees to hold any communication by the Issuer in response to a Sale Notice in confidence. 
  

 12 

 5. Registration Expenses. 
  
 (a) All expenses incident to the Issuer’s performance of or compliance with this Agreement shall be borne by the Issuer
regardless of whether a Shelf Registration Statement becomes effective, including, without limitation: 
  
 (i) all registration and filing fees and expenses (including filings made by any Initial Purchasers, Holders or underwriters with the
NASD); 
  
 (ii) all fees and expenses of
compliance with federal securities and state Blue Sky or securities laws; 
  
 (iii) all expenses of printing (including printing of Prospectuses and certificates for the Common Stock to be issued upon conversion of the Debentures), messenger and delivery services and telephone; 
  
 (iv) all fees and disbursements of counsel to the Issuer
and, subject to Section 5(b) below, the Holders of Transfer Restricted Securities; 
  
 (v) all application and filing fees in connection with listing (or authorizing for quotation) the Common Stock on a national securities
exchange or automated quotation system pursuant to the requirements hereof; and 
  
 (vi) all fees and disbursements of independent certified public accountants of the Issuer (including the expenses of any special audit and
comfort letters required by or incident to such performance). 
  
 The Issuer shall
bear its internal expenses (including, without limitation, all salaries and expenses of their officers and employees performing legal, accounting or other duties), the expenses of any annual audit and the fees and expenses of any Person, including
special experts, retained by the Issuer. 
  
 (b) In connection
with the review of the Shelf Registration Statement and other documents referred to in this Agreement, the Issuer shall, against a reasonably detailed invoice therefor, reimburse Citigroup, on behalf of the Initial Purchasers, and the Holders of
Transfer Restricted Securities being registered pursuant to the Shelf Registration Statement, for the reasonable fees and disbursements of not more than one counsel, which shall be Cahill Gordon & Reindel LLP, or such other counsel as may be
chosen by a Majority of Holders for whose benefit the Shelf Registration Statement is being prepared. 
  
 6. Indemnification and Contribution. 
  
 (a) The Issuer agrees to indemnify and hold harmless each Initial Purchaser, each Holder whose securities are included in a Shelf Registration Statement,
each Person who participates as an underwriter (any such Person being an “Underwriter”) and each Person, if any, who controls any Initial Purchaser, Holder or Underwriter within the meaning of either Section 15 of the Securities Act
or Section 20 of the Exchange Act as follows: 
  

 13 

 (i) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in such Shelf Registration Statement (or any amendment thereto), including all documents incorporated therein by reference, or the omission or
alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact contained in any Prospectus
(or any amendment or supplement thereto) or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 
  
 (ii) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any
such untrue statement or omission, or any such alleged untrue statement or omission; provided, however that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Issuer; and 
  
 (iii) against any and all expense whatsoever, as incurred
(including the fees and disbursements of counsel chosen by any indemnified party), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under subparagraph (i) or (ii) above; provided,
however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with written information furnished to the Issuer by the Initial Purchasers, such Holder or such Underwriter expressly for use in a Shelf Registration Statement (or any amendment thereto) or any Prospectus (or any amendment or supplement
thereto). 
  
 (b) Each Holder whose securities are included in a
Shelf Registration Statement, severally but not jointly, agrees to indemnify and hold harmless the Issuer, the Initial Purchasers, each Underwriter and the other selling Holders and each Person, if any, who controls the Issuer, the Initial
Purchasers, any Underwriter or any other selling Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in
Section 6(a) hereof, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in such Shelf Registration Statement (or any amendment thereto) or any Prospectus (or any amendment or
supplement thereto) in reliance upon and in conformity with written information with respect to such Holder furnished to the Issuer by such Holder expressly for use in such Shelf Registration Statement (or any amendment thereto) or such Prospectus
(or any amendment or supplement thereto); provided, however, that no such Holder shall be liable for any claims hereunder in excess of the amount of net proceeds received by such Holder from the sale of Transfer Restricted Securities
pursuant to such Shelf Registration Statement. 
  

 14 

 (c) Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action or proceeding commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is
not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. An indemnifying party may participate at its own expense in the defense
of such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying party or parties be
liable for the fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same
jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any
litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 (whether or not the
indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding
or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
  
 (d) If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel,
such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying
party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such settlement; provided, however, that an indemnifying party shall not be liable for any such settlement if such indemnifying party (1) reimburses such
indemnified party in accordance with such request for the amount of such fees and expenses of such counsel as the indemnifying party believes in good faith to be reasonable and (2) provides written notice to the indemnified party and the
indemnifying party disputes in good faith the reasonable ness of the unpaid balance of such fees and expenses. 
  
 (e) If the indemnification provided for in this Section 6 is for any reason unavailable to or insufficient to hold harmless an indemnified party in
respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party,
as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Issuer from the offering and sale of the Transfer Restricted Securities on the one hand and a Holder with respect to the sale by the Holder of the
Transfer Restricted Securities on the other hand; or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in 
  

 15 

 
clause (i) but also the relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand in
connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. 
  
 The relative benefits received by the Issuer on the one hand and a Holder on the other hand with respect to such offering
and such sale shall be deemed to be in the same proportion as the total net proceeds from the offering of the Debentures purchased under the Purchase Agreement (before deducting expenses) received by the Issuer, as set forth in the Offering
Memorandum dated June 13, 2003 relating to the Debentures on the one hand bear to the total net proceeds received by such Holder with respect to its sale of Transfer Restricted Securities on the other. The relative fault of the indemnifying party or
parties on the one hand and the indemnified party or parties on the other hand shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact relates to information supplied by the indemnifying party or parties on the one hand or the indemnified party or parties on the other hand and the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. 
  
 The parties
hereto agree that it would not be just and equitable if contribution pursuant to this Section 6 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above
in this Section 6. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 6 shall be deemed to include any legal or other expenses reasonably incurred by such
indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission. 
  
 Notwithstanding the
provisions of this Section 6, no Holder shall be required to contribute any amount in excess of the amount by which the total price at which the Transfer Restricted Securities purchased by it were resold exceeds the amount of any damages which such
Holder has otherwise been required to pay by reason of any untrue or alleged untrue statement or omission or alleged omission. The Holders’ obligations to contribute as provided in this Section 6(e) are several and not joint. No Person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 For purposes of this Section 6, each Person, if any, who controls an Initial
Purchaser, a Holder or an Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same rights to contribution as such Initial Purchaser, such Holder or such Underwriter, and each director
of the Issuer, and each Person, if any, who controls the Issuer within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same rights to contribution as the Issuer. 
  
 7. Rule 144A. In the event the Issuer is not subject to Section 13 or
15(d) of the Exchange Act, the Issuer hereby agrees with each Holder, for so long as any Transfer Re- 
  

 16 

 
stricted Securities remain outstanding, to make available to any Holder or beneficial owner of Transfer Restricted Securities in connection with any sale
thereof and any prospective purchaser of such Transfer Restricted Securities from such Holder or beneficial owner, the information required by Rule 144A(d)(4) under the Securities Act in order to permit resales of such Transfer Restricted Securities
pursuant to Rule 144A. 
  
 8. Participation in Underwritten
Registrations. No Holder may participate in any Underwritten Registration hereunder unless such Holder: 
  
 (i) agrees to sell such Holder’s Transfer Restricted Securities on the basis provided in any underwriting arrangements approved by
the Persons entitled hereunder to approve such arrangements, and 
  
 (ii) completes and executes all reasonable questionnaires, powers of attorney, indemnities, underwriting agreements, lock-up letters and other documents required under the terms of such underwriting arrangements.

  
 9. Selection of Underwriters. The Holders of Transfer
Restricted Securities covered by the Shelf Registration Statement who desire to do so may sell such Transfer Restricted Securities in an Underwritten Offering. In any such Underwritten Offering, the investment banker or investment bankers and
manager or managers that will administer the offering will be selected by a Majority of Holders whose Transfer Restricted Securities are included in such offering; provided, that such investment bankers and managers must be reasonably satisfactory
to the Issuer. 
  
 10. Miscellaneous. 
  
 (a) Remedies. The Issuer acknowledges and agrees that any failure by
the Issuer to comply with its obligations under Section 2 hereof may result in material irreparable injury to the Initial Purchasers or the Holders for which there is no adequate remedy at law, that it will not be possible to measure damages for
such injuries precisely and that, in the event of any such failure, the Initial Purchasers or any Holder may obtain such relief as may be required to specifically enforce the Issuer’s obligations under Section 2 hereof. The Issuer further
agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. 
  
 (b) Adjustments Affecting Transfer Restricted Securities. The Issuer shall not, directly or indirectly, take any action with respect to the
Transfer Restricted Securities as a class that would adversely affect the ability of the Holders to include such Transfer Restricted Securities in a registration undertaken pursuant to this Agreement. 
  
 (c) No Inconsistent Agreements. The Issuer will not, on or after the
date of this Agreement, enter into any agreement with respect to its securities that is inconsistent with the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. In addition, the Issuer shall not, on or
after the date hereof, grant to any of its security holders (other than the holders of Transfer Restricted Securities in such capacity) the right to include any of its securities in the Shelf Registration Statement provided for in this Agreement

  

 17 

 
other than the Transfer Restricted Securities. Except as disclosed in the Offering Memorandum dated June 13, 2003 relating to the Debentures, the Issuer has
not previously entered into any agreement (which has not expired or been terminated) granting any registration rights with respect to its securities to any Person which rights conflict with the provisions hereof. 
  
 (d) Amendments and Waivers. This Agreement may not be amended,
modified or supplemented, and waivers or consents to or departures from the provisions hereof may not be given, unless the Issuer has obtained the written consent of a Majority of Holders. 
  
 (e) Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand-delivery, first-class mail (registered or certified, return receipt requested), telex, telecopier, or air courier guaranteeing overnight delivery: 
  
 (i) if to a Holder, at the address set forth on the records
of the registrar under the Indenture or the transfer agent of the Common Stock, as the case may be; and 
  
 (ii) if to the Issuer: 
  
 CV Therapeutics, Inc. 
 3172 Porter Drive 
 Palo Alto, California 94304 
 Attention: Tricia Borga Suvari 
  
 With a copy (which shall not constitute notice) to: 
  
 Latham & Watkins LLP. 
 135 Commonwealth Drive 
 Menlo Park, California 94025 
 Attention: Alan C. Mendelson, Esq. 
  
 All such notices and communications shall be deemed to have been duly given: at the time
delivered by hand, if personally delivered; five Business Days after being deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt acknowledged, if telecopied; and on the next Business Day, if timely delivered
to an air courier guaranteeing overnight delivery. 
  
 (f)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties, including without limitation and without the need for an express assignment, subsequent Holders of
Transfer Restricted Securities; provided, however, that (i) this Agreement shall not inure to the benefit of or be binding upon a successor or assign of a Holder unless and to the extent such successor or assign acquired Transfer Restricted
Securities from such Holder and (ii) nothing contained herein shall be deemed to permit any assignment, transfer or other disposition of Transfer Restricted Securities in violation of the terms of the Purchase Agreement or the Indenture. If any
transferee of any Holder shall acquire Transfer Restricted Securities, in any manner, whether by operation of law or otherwise, such Transfer Restricted Securities shall be held subject to all of the terms of this Agreement, and by taking and
holding such Transfer Restricted Securities such person shall be 

  

 18 

 
conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement. 
  
 (g) Counterparts. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 
  
 (h) Securities Held by the Issuer or Their Affiliates. Whenever the
consent or approval of Holders of a specified percentage of Transfer Restricted Securities is required hereunder, Transfer Restricted Securities held by the Issuer or its “affiliates” (as such term is defined in Rule 405 under the
Securities Act) shall not be counted in determining whether such consent or approval was given by the Holders of such required percentage. 
  
 (i) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

  
 (j) Governing Law. This Agreement shall be governed by,
and construed in accordance with, the law of the State of New York. 
  
 (k) Severability. If any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in
every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby. 
  
 (l) Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and
exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein with
respect to the registration rights granted by the Issuer with respect to the Transfer Restricted Securities. This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter. 
  

 19 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

	CV THERAPEUTICS, INC.
		
	 By:
	 	 /s/    LOUIS G. LANGE, M.D., PH.D.

	 	 	 Name:
	 	 Louis G. Lange, M.D., Ph.D.

	 	 	 Title:
	 	 Chairman and Chief Executive Officer

  

 20 

	 Accepted as of the date
 first set forth above:

	
	 CITIGROUP GLOBAL MARKETS INC.

	 CIBC WORLD MARKETS CORP.

	 DEUTSCHE BANK SECURITIES INC.

	 FIRST ALBANY CORPORATION

	 NEEDHAM & COMPANY, INC.

	 SG COWEN SECURITIES CORPORATION

		
	 By:
	 	 CITIGROUP GLOBAL MARKETS INC.

		
	 By:
	 	 /s/    MARK SIMON

	 	 	 Name: Mark Simon

	 	 	 Title: Managing Director

		
	 	 	 Acting on behalf of itself and the other Initial
 Purchasers

  
  

 21 

 Exhibit A 
  
 CV THERAPEUTICS, INC. 
  
 INSTRUCTION TO DTC PARTICIPANTS 
  
 [            ], 2003 
  
 URGENT - IMMEDIATE ATTENTION REQUESTED 
  
 DEADLINE FOR RESPONSE: [            ], 2003

  
 The Depository Trust Company (“DTC”) has
identified you as a DTC Participant through which beneficial interests in the CV Therapeutics, Inc. (the “Issuer”) 2.0% Senior Subordinated Convertible Debentures due May 16, 2023 (the “Securities”) are held.

  
 The Issuer is in the process of registering the Securities
under the Securities Act of 1933, as amended, for resale by the beneficial owners thereof. In order to have their Securities included in the registration statement, beneficial owners must complete and return the enclosed Notice of Registration
Statement and Selling Securityholder Questionnaire. 
  
 It is
important that beneficial owners of the Securities receive a copy of the enclosed materials as soon as possible as their rights to have the Securities included in the registration statement depend upon their returning the Notice and
Questionnaire by [            ], 2003. Please forward a copy of the enclosed documents to each beneficial owner that holds interests in the Securities through you. If you require
more copies of the enclosed materials or have any questions pertaining to this matter, please contact Tricia Borga Suvari, CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304. 

 CV THERAPEUTICS, INC. 
  
 Notice of Registration Statement 
  
 and 
  
 Selling Securityholder Questionnaire 
  
 [            ], 2003 
  
 Reference is hereby made to the Registration Rights Agreement, dated as of June 18, 2003 (the “Registration Rights
Agreement”) between CV Therapeutics, Inc. (the “Issuer”) and Citigroup Global Markets Inc., CIBC World Markets Corp., Deutsche Bank Securities Inc., First Albany Corporation, Needham & Company, Inc. and SG Cowen
Securities Corporation. Pursuant to the Registration Rights Agreement, the Issuer plans to file with the United States Securities and Exchange Commission (the “Commission”) a registration statement on Form S-3 (the “Shelf
Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Issuer’s 2.0% Senior Subordinated Convertible Debentures due May 16, 2023
(the “Securities”) and the shares of common stock, par value $.001 per share (the “Shares”), issuable upon conversion thereof. A copy of the Registration Rights Agreement is attached hereto. All capitalized terms
not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 
  
 Each beneficial owner of Registrable Securities (as defined below) is entitled to have the Registrable Securities beneficially owned by it included in the
Shelf Registration Statement. In order to have Registrable Securities included in the Shelf Registration Statement, this Notice of Registration Statement and Selling Securityholder Questionnaire (“Notice and Questionnaire”) must be
completed, executed and delivered to the Issuer’s counsel at the address set forth herein for receipt ON OR BEFORE [            ], 2003. Beneficial owners of Registrable
Securities who do not complete, execute and return this Notice and Questionnaire by such date (i) will not be named as selling securityholders in the Shelf Registration Statement and (ii) may not use the Prospectus forming a part thereof for resales
of Registrable Securities. 
  
 Certain legal consequences arise
from being named as a selling securityholder in the Shelf Registration Statement and related Prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel 

 
regarding the consequences of being named or not being named as a selling securityholder in the Shelf Registration Statement and related Prospectus.

  
 The term “Registrable Securities” is defined
as all or any portion of the Securities issued from time to time under the Indenture in registered form and the Shares issuable upon conversion of such Securities; provided, however, that a security ceases to be a Registrable Security
when it is no longer a Transfer Restricted Security. 
  
 The term
“Transfer Restricted Security” is defined in the Registration Rights Agreement to mean each Debenture and each share of Common Stock issued upon conversion of Debentures until the earlier of: 
  
 (i) the date on which such Debenture or such share of Common
Stock issued upon conversion has been effectively registered under the Securities Act and disposed of in accordance with the Shelf Registration Statement; 
  
 (ii) the date on which such Debenture or such share of Common Stock issued upon conversion is transferred in compliance with Rule 144
under the Securities Act or may be sold or transferred pursuant to Rule 144(k) under the Securities Act (or any other similar provision then in force); or 
  
 (iii) the date on which such Debenture or such share of Common Stock issued upon conversion ceases to be outstanding (whether as a result
of redemption, repurchase and cancellation, conversion or otherwise). 
  
 ELECTION 
  
 The undersigned holder (the
“Selling Securityholder”) of Registrable Securities hereby elects to include in the Shelf Registration Statement the Registrable Securities beneficially owned by it and listed below in Item (3). The undersigned, by signing and
returning this Notice and Questionnaire, agrees to be bound with respect to such Registrable Securities by the terms and conditions of this Notice and Questionnaire and the Registration Rights Agreement, including, without limitation, Section 6 of
the Registration Rights Agreement, as if the undersigned Selling Securityholder were an original party thereto. 
  
 Upon any sale of Registrable Securities pursuant to the Shelf Registration Statement, the Selling Securityholder will be required to deliver to the Issuer
and Trustee the Notice of Transfer set forth as Exhibit B to the Registration Rights Agreement. 
  
 The Selling Securityholder hereby provides the following information to the Issuer and represents and warrants that such information is accurate and
complete: 
  

 24 

 QUESTIONNAIRE 
  

			
	 (1)
	  	(a)	 	Full Legal Name of Selling Securityholder:
			
	 	  	 	 	

			
	 	  	(b)	 	Full Legal Name of Registered Holder (if not the same as in (a) above) of Registrable Securities Listed in Item (3) below:
			
	 	  	 	 	

			
	 	  	(c)	 	Full Legal Name of DTC Participant (if applicable and if not the same as (b) above) Through Which Registrable Securities Listed in Item (3) below are
Held:
			
	 	  	 	 	

			
	 (2)
	  	 	 	Address for Notices to Selling Securityholder:
				
	 	  	 	 	 	  	

	 	  	 	 	 	  	

	 	  	 	 	 	  	

	 	  	 	 	Telephone:	  	

	 	  	 	 	Fax:	  	

	 	  	 	 	Contact Person:	  	

			
	 (3)
	  	 	 	Beneficial Ownership of Securities:
			
	 	  	 	 	Except as set forth below in this Item (3), the undersigned does not beneficially own any Securities or Shares issued upon conversion of any
Securities.
			
	 	  	(a)	 	Principal amount at maturity of Registrable Securities beneficially owned:
			
	 	  	 	 	

			
	 	  	 	 	CUSIP No(s). of such Registrable Securities:
			
	 	  	 	 	

			
	 	  	 	 	Number of Shares (if any) issued upon conversion of such Registrable Securities:
			
	 	  	 	 	

			
	 	  	(b)	 	Principal amount at maturity of Securities other than Registrable Securities beneficially owned:
			
	 	  	 	 	

			
	 	  	 	 	 CUSIP No(s). of such other Securities:                           
                                        
                                        
                                     

			
	 	  	 	 	Number of Shares (if any) issued upon conversion of such other Securities:

			
	 	  	 	 	

			
	 	  	(c)	 	Principal amount at maturity of Registrable Securities which the undersigned wishes to be included in the Shelf Registration Statement:
			
	 	  	 	 	

			
	 	  	 	 	CUSIP No(s). of such Registrable Securities to be included in the Shelf Registration Statement:
			
	 	  	 	 	

			
	 	  	 	 	Number of Shares (if any) issued upon conversion of Registrable Securities which are to be included in the Shelf Registration Statement:
			
	 	  	 	 	

			
	 (4)
	  	 	 	Beneficial Ownership of Other Securities of the Issuer:
			
	 	  	 	 	Except as set forth in this Item (4), the undersigned Selling Securityholder is not the beneficial or registered owner of any Shares or any other securities of the Issuer,
other than the Securities and Shares listed above in Item (3).
			
	 	  	 	 	State any exceptions here:
			
	 (5)
	  	 	 	Relationships with the Issuer:
			
	 	  	 	 	Except as set forth below, neither the Selling Securityholder nor any of its affiliates, officers, directors or principal equity holders (5% or more) has held any position or
office or has had any other material relationship with the Issuer (or its predecessors or affiliates) during the past three years.
			
	 	  	 	 	State any exceptions here:
			
	 (6)
	  	 	 	Plan of Distribution:
			
	 	  	 	 	Except as set forth below, the undersigned Selling Securityholder intends to distribute the Registrable Securities listed above in Item (3) only as follows (if at all): Such
Registrable Securities may be sold from time to time directly by the undersigned Selling Securityholder or, alternatively, through underwriters, broker-dealers or agents. Such Registrable Securities may be sold in one or more transactions at fixed
prices, at prevailing market prices at the time of sale, at varying prices determined at the time of sale, or at negotiated prices. Such sales may be effected in transactions (which may involve crosses or block transactions) (i) on any national
securities exchange or quotation service on which the Registered Securities

  

 2 

	 	  	 	  	 may be listed or quoted at the time of sale, (ii) in the over-the-counter market, (iii) in transactions otherwise than on such exchanges or
services or in the over-the-counter market, or (iv) through the writing of options. In connection with sales of the Registrable Securities in the course of hedging the positions they assume. The Selling Securityholder may also sell Registrable
Securities short and deliver Registrable Securities to close out such short positions, or loan or pledge Registrable Securities to broker-dealers that in turn may sell such securities.

			
	 	  	 	  	 State any exceptions here:

  
 Note: In no event may
such method(s) of distribution take the form of an underwritten offering of the Registrable Securities without the prior agreement of the Issuer. 
  
 By signing below, the Selling Securityholder acknowledges that it understands its obligation to comply, and agrees that it will comply, with the
provisions of the Exchange Act and the rules to regulations thereunder, particularly Regulation M. 
  
 In the event that the Selling Securityholder transfers all or any portion of the Registrable Securities listed in Item (3) above after the date on which
such information is provided to the Issuer, the Selling Securityholder agrees to notify in writing the Issuer and any transferee(s) at the time of the transfer of its rights and obligations under this Notice and Questionnaire and the Registration
Rights Agreement. 
  
 By signing below, the Selling Securityholder
consents to the disclosure of the information contained herein in its answers to Items (1) through (6) above and the inclusion of such information in the Shelf Registration Statement and related Prospectus. The Selling Securityholder understands
that such information will be relied upon by the Issuer in connection with the preparation of the Shelf Registration Statement and related Prospectus. 
  
 In accordance with the Selling Securityholder’s obligation under Section 2(b) of the Registration Rights Agreement to provide such information as may
be required by law for inclusion in the Shelf Registration Statement, the Selling Securityholder agrees to promptly notify the Issuer in writing of any inaccuracies or changes in the information provided herein which may occur subsequent to the date
hereof at any time while the Shelf Registration Statement remains in effect. All notices hereunder and pursuant to the Registration Rights Agreement shall be made in writing, by hand-delivery, first class mail, or air courier guaranteeing overnight
delivery as follows: 
  

 3 

 To the Issuer: 
  

	 CV Therapeutics, Inc.

	 3172 Porter Drive

	 Palo Alto, California 94304

	 Telephone: (650) 384-8500

	 Facsimile: (650) 858-0388

	 Attention: Tricia Borga Suvari

  
 With a copy (which shall not constitute notice) to: 
  

	 Latham & Watkins LLP

	 135 Commonwealth Drive

	 Menlo Park, California 94025

	 Telephone: (650) 463-4693

	 Facsimile: (650) 463-2600

	 Attention: Alan C. Mendelson, Esq.

  
 Once this Notice
and Questionnaire is executed by the Selling Securityholder and received by the Issuer’s counsel, the terms of this Notice and Questionnaire, and the representations and warranties contained herein, shall be binding on, shall inure to the
benefit of and shall be enforceable by the respective successors, heirs, personal representatives, and assigns of the Issuer and the Selling Securityholder (with respect to the Registrable Securities beneficially owned by such Selling Securityholder
and listed in Item (3) above). This Agreement shall be governed in all respects by the laws of the State of New York. 
  
 IN WITNESS WHEREOF, the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by
its duly authorized agent. 
  
 Dated:
                                 
  

		
	 	 	

	 	 	 Selling Securityholder

	 	 	 	  	(Print/type full legal name of beneficial owner of Registrable Securities)

  

	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

  
 PLEASE RETURN THE COMPLETED AND
EXECUTED NOTICE AND QUESTIONNAIRE FOR RECEIPT ON OR BEFORE [            ], 2003 TO THE ISSUER’S COUNSEL AT: 
  

 4 

	 Latham & Watkins LLP

	 135 Commonwealth Drive

	 Menlo Park, California 94025

	 Telephone: (650) 463-4693

	 Facsimile: (650) 463-2600

	 Attention: Alan C. Mendelson, Esq.

  
  

 5 

 Exhibit B 
  
 NOTICE OF TRANSFER PURSUANT TO REGISTRATION STATEMENT 
  
 Wells Fargo Bank Minnesota, N.A. 
 Sixth &
Marquette 
 MAC N9303 120 
 Minneapolis, Minnesota 55479

 Attention: [Corporate Trust Services] 
  

	 Re:
	 	 CV Therapeutics, Inc.
 2.0% Senior Subordinated Convertible Debentures
 due May 16, 2023 (the “Debentures”) 

  
 Dear
Sirs: 
  
 Please be advised that
                                     has transferred $
             aggregate principal amount at maturity (subject to upward adjustment in the event of an upward interest adjustment) of the above-referenced Debentures pursuant to an
effective Registration Statement on Form [            ] (File No. 333-            ) filed by the Issuer.

  
 We hereby certify that the prospectus delivery requirements,
if any, of the Security Act of 1933, as amended, have been satisfied and that the above-named beneficial owner of the Debentures is named as a “Selling Holder” in the Prospectus dated
                                 , or in supplements thereto, and that the
aggregate principal amount of the Debentures transferred are the Debentures listed in such Prospectus opposite such owner’s name. 
  

	 	 	 Very truly yours,

		
	 	 	

	 	 	 (Name)

		
	 By:
	 	  

	 	 	 (Authorized Signature)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]